advertisement

List of abstracts related to

Listed by Classification

14 Costing studies; pharmacoeconomics (832 abstracts found)

94503 Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana
Ofei-Palm CNK
ClinicoEconomics and outcomes research : CEOR 2021; 13: 619-627 (IGR: 22-2)

95048 A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France
Nieland K
PLoS ONE 2021; 16: e0252130 (IGR: 22-2)

94810 Impact of discontinuing government-funded routine eye exams on new glaucoma diagnoses in Ontario
Jin YP
Canadian Journal of Ophthalmology 2022; 57: 319-327 (IGR: 22-2)

94503 Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana
Tagoe NN
ClinicoEconomics and outcomes research : CEOR 2021; 13: 619-627 (IGR: 22-2)

94810 Impact of discontinuing government-funded routine eye exams on new glaucoma diagnoses in Ontario
Buys YM
Canadian Journal of Ophthalmology 2022; 57: 319-327 (IGR: 22-2)

95048 A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France
Labbé A; Schweitzer C
PLoS ONE 2021; 16: e0252130 (IGR: 22-2)

94503 Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana
Jatoe D
ClinicoEconomics and outcomes research : CEOR 2021; 13: 619-627 (IGR: 22-2)

94810 Impact of discontinuing government-funded routine eye exams on new glaucoma diagnoses in Ontario
Vujicic M; El-Defrawy S
Canadian Journal of Ophthalmology 2022; 57: 319-327 (IGR: 22-2)

95048 A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France
Gicquel G
PLoS ONE 2021; 16: e0252130 (IGR: 22-2)

94503 Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana
Agyare A
ClinicoEconomics and outcomes research : CEOR 2021; 13: 619-627 (IGR: 22-2)

94810 Impact of discontinuing government-funded routine eye exams on new glaucoma diagnoses in Ontario
El-Defrawy S; Brent MH
Canadian Journal of Ophthalmology 2022; 57: 319-327 (IGR: 22-2)

95048 A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France
Kleintjens J
PLoS ONE 2021; 16: e0252130 (IGR: 22-2)

94503 Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana
Ankrah D
ClinicoEconomics and outcomes research : CEOR 2021; 13: 619-627 (IGR: 22-2)

94810 Impact of discontinuing government-funded routine eye exams on new glaucoma diagnoses in Ontario
Jeon W
Canadian Journal of Ophthalmology 2022; 57: 319-327 (IGR: 22-2)

95048 A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France
Ostawal A; Treur M
PLoS ONE 2021; 16: e0252130 (IGR: 22-2)

94810 Impact of discontinuing government-funded routine eye exams on new glaucoma diagnoses in Ontario
Trope GE
Canadian Journal of Ophthalmology 2022; 57: 319-327 (IGR: 22-2)

95048 A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France
Falvey H
PLoS ONE 2021; 16: e0252130 (IGR: 22-2)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
Shih V; Shih V
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92601 Evaluating multidisciplinary glaucoma care: visual field progression and loss of sight year analysis in the community vs hospital setting
Mushtaq Y
Eye 2022; 36: 555-563 (IGR: 22-1)

92777 The Effect of Market Competition on the Price of Topical Eye Drops
Watane A
Seminars in Ophthalmology 2021; 0: 1-7 (IGR: 22-1)

92044 Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis
Patel AR
Journal of Glaucoma 2021; 30: 242-250 (IGR: 22-1)

92046 Changes in Prices and Eye-Care Providers Prescribing Patterns of Glaucoma Medications in the United States Between 2013 and 2019
Barayev E
Journal of Glaucoma 2021; 30: e83-e89 (IGR: 22-1)

92445 Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study
Beal B
Clinical Ophthalmology 2021; 15: 453-460 (IGR: 22-1)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
Shih V
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92426 A Scoping Review of Process Indicators for Measuring Quality of Care in Glaucoma
Iorio-Aranha F
Journal of Glaucoma 2021; 30: e198-e204 (IGR: 22-1)

92733 Health economic evaluation in ophthalmology
Atik A
British Journal of Ophthalmology 2021; 105: 602-607 (IGR: 22-1)

92000 Impact of iStent Micro-Bypass Shunt on Medicare Part B Glaucoma Surgical Expenditure
Lee JH
Ophthalmology. Glaucoma 2021; 4: 131-138 (IGR: 22-1)

92059 Medical Costs of and Changes in Glaucoma Treatment among Patients Newly Starting Glaucoma Care
Fukuda Y
Current Eye Research 2021; 0: 1-8 (IGR: 22-1)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
Parekh M
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92000 Impact of iStent Micro-Bypass Shunt on Medicare Part B Glaucoma Surgical Expenditure
Ma AK
Ophthalmology. Glaucoma 2021; 4: 131-138 (IGR: 22-1)

92445 Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study
Shih V
Clinical Ophthalmology 2021; 15: 453-460 (IGR: 22-1)

92733 Health economic evaluation in ophthalmology
Barton K
British Journal of Ophthalmology 2021; 105: 602-607 (IGR: 22-1)

92046 Changes in Prices and Eye-Care Providers Prescribing Patterns of Glaucoma Medications in the United States Between 2013 and 2019
Geffen N
Journal of Glaucoma 2021; 30: e83-e89 (IGR: 22-1)

92426 A Scoping Review of Process Indicators for Measuring Quality of Care in Glaucoma
Peleteiro B
Journal of Glaucoma 2021; 30: e198-e204 (IGR: 22-1)

92445 Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study
Shih V
Clinical Ophthalmology 2021; 15: 453-460 (IGR: 22-1)

92059 Medical Costs of and Changes in Glaucoma Treatment among Patients Newly Starting Glaucoma Care
Kume A
Current Eye Research 2021; 0: 1-8 (IGR: 22-1)

92044 Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis
Schwartz GF
Journal of Glaucoma 2021; 30: 242-250 (IGR: 22-1)

92601 Evaluating multidisciplinary glaucoma care: visual field progression and loss of sight year analysis in the community vs hospital setting
Panchasara B
Eye 2022; 36: 555-563 (IGR: 22-1)

92445 Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study
Shih V
Clinical Ophthalmology 2021; 15: 453-460 (IGR: 22-1)

92777 The Effect of Market Competition on the Price of Topical Eye Drops
Kalavar M
Seminars in Ophthalmology 2021; 0: 1-7 (IGR: 22-1)

92046 Changes in Prices and Eye-Care Providers Prescribing Patterns of Glaucoma Medications in the United States Between 2013 and 2019
Nahum Y
Journal of Glaucoma 2021; 30: e83-e89 (IGR: 22-1)

92445 Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study
Campbell J
Clinical Ophthalmology 2021; 15: 453-460 (IGR: 22-1)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
Multani JK
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92044 Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis
Campbell JH
Journal of Glaucoma 2021; 30: 242-250 (IGR: 22-1)

92601 Evaluating multidisciplinary glaucoma care: visual field progression and loss of sight year analysis in the community vs hospital setting
Nassehzadehtabriz N
Eye 2022; 36: 555-563 (IGR: 22-1)

92059 Medical Costs of and Changes in Glaucoma Treatment among Patients Newly Starting Glaucoma Care
Kashiwagi K
Current Eye Research 2021; 0: 1-8 (IGR: 22-1)

92000 Impact of iStent Micro-Bypass Shunt on Medicare Part B Glaucoma Surgical Expenditure
Warren JL
Ophthalmology. Glaucoma 2021; 4: 131-138 (IGR: 22-1)

92426 A Scoping Review of Process Indicators for Measuring Quality of Care in Glaucoma
Rocha-Sousa A
Journal of Glaucoma 2021; 30: e198-e204 (IGR: 22-1)

92733 Health economic evaluation in ophthalmology
Azuara-Blanco A
British Journal of Ophthalmology 2021; 105: 602-607 (IGR: 22-1)

92777 The Effect of Market Competition on the Price of Topical Eye Drops
Reyes J
Seminars in Ophthalmology 2021; 0: 1-7 (IGR: 22-1)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
Multani JK
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92733 Health economic evaluation in ophthalmology
Kerr NM
British Journal of Ophthalmology 2021; 105: 602-607 (IGR: 22-1)

92777 The Effect of Market Competition on the Price of Topical Eye Drops
Yannuzzi NA
Seminars in Ophthalmology 2021; 0: 1-7 (IGR: 22-1)

92445 Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study
Veenstra D
Clinical Ophthalmology 2021; 15: 453-460 (IGR: 22-1)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
McGuiness CB
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92044 Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis
Chen CC
Journal of Glaucoma 2021; 30: 242-250 (IGR: 22-1)

92000 Impact of iStent Micro-Bypass Shunt on Medicare Part B Glaucoma Surgical Expenditure
Teng CC
Ophthalmology. Glaucoma 2021; 4: 131-138 (IGR: 22-1)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
McGuiness CB
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92601 Evaluating multidisciplinary glaucoma care: visual field progression and loss of sight year analysis in the community vs hospital setting
Lim HK
Eye 2022; 36: 555-563 (IGR: 22-1)

92046 Changes in Prices and Eye-Care Providers Prescribing Patterns of Glaucoma Medications in the United States Between 2013 and 2019
Gershoni A
Journal of Glaucoma 2021; 30: e83-e89 (IGR: 22-1)

92426 A Scoping Review of Process Indicators for Measuring Quality of Care in Glaucoma
Azevedo A; Barbosa-Breda J
Journal of Glaucoma 2021; 30: e198-e204 (IGR: 22-1)

92044 Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis
McGuiness CB
Journal of Glaucoma 2021; 30: 242-250 (IGR: 22-1)

92601 Evaluating multidisciplinary glaucoma care: visual field progression and loss of sight year analysis in the community vs hospital setting
Mushtaq M
Eye 2022; 36: 555-563 (IGR: 22-1)

92777 The Effect of Market Competition on the Price of Topical Eye Drops
Sridhar J
Seminars in Ophthalmology 2021; 0: 1-7 (IGR: 22-1)

92044 Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis
McGuiness CB
Journal of Glaucoma 2021; 30: 242-250 (IGR: 22-1)

92445 Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study
Devine B
Clinical Ophthalmology 2021; 15: 453-460 (IGR: 22-1)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
Chen CC
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92044 Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis
Multani JK
Journal of Glaucoma 2021; 30: 242-250 (IGR: 22-1)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
Campbell JH
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92044 Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis
Multani JK
Journal of Glaucoma 2021; 30: 242-250 (IGR: 22-1)

92601 Evaluating multidisciplinary glaucoma care: visual field progression and loss of sight year analysis in the community vs hospital setting
Kean J; Farrell S
Eye 2022; 36: 555-563 (IGR: 22-1)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
Miller-Ellis E
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92044 Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis
Shih V; Shih V; Shih V
Journal of Glaucoma 2021; 30: 242-250 (IGR: 22-1)

92601 Evaluating multidisciplinary glaucoma care: visual field progression and loss of sight year analysis in the community vs hospital setting
Bourne RRA
Eye 2022; 36: 555-563 (IGR: 22-1)

92484 Clinical and Economic Burden of Glaucoma by Disease Severity: A United States Claims-Based Analysis
Olivier MMG
Ophthalmology. Glaucoma 2021; 0: (IGR: 22-1)

92044 Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis
Smith OU
Journal of Glaucoma 2021; 30: 242-250 (IGR: 22-1)

92601 Evaluating multidisciplinary glaucoma care: visual field progression and loss of sight year analysis in the community vs hospital setting
Shahid H; Khatib TZ; Martin KR
Eye 2022; 36: 555-563 (IGR: 22-1)

91830 Population-Based Projection of Vision-Related Disability in Australia 2020 - 2060: Prevalence, Causes, Associated Factors and Demand for Orientation and Mobility Services
Chang KJ
Ophthalmic Epidemiology 2021; 0: 1-10 (IGR: 21-4)

90973 Surgical Cancellations in Glaucoma Practice: Causes, Delays, and Effect on Patient Care and Revenue
Mehran N
Ophthalmology. Glaucoma 2021; 4: 427-432 (IGR: 21-4)

91126 Distribution and Predictors of Initial Glaucoma Care among Ophthalmologists and Optometrists: A Population-based Study
Quinn MP
Journal of Glaucoma 2021; 30: e300-e304 (IGR: 21-4)

91337 Changes in Performance of Glaucoma Surgeries 1994 through 2017 Based on Claims and Payment Data for United States Medicare Beneficiaries
Boland MV
Ophthalmology. Glaucoma 2021; 4: 463-471 (IGR: 21-4)

90973 Surgical Cancellations in Glaucoma Practice: Causes, Delays, and Effect on Patient Care and Revenue
Mehran N
Ophthalmology. Glaucoma 2021; 4: 427-432 (IGR: 21-4)

91126 Distribution and Predictors of Initial Glaucoma Care among Ophthalmologists and Optometrists: A Population-based Study
Quinn MP; Johnson D
Journal of Glaucoma 2021; 30: e300-e304 (IGR: 21-4)

91337 Changes in Performance of Glaucoma Surgeries 1994 through 2017 Based on Claims and Payment Data for United States Medicare Beneficiaries
Corcoran KJ
Ophthalmology. Glaucoma 2021; 4: 463-471 (IGR: 21-4)

90973 Surgical Cancellations in Glaucoma Practice: Causes, Delays, and Effect on Patient Care and Revenue
Ojalvo I
Ophthalmology. Glaucoma 2021; 4: 427-432 (IGR: 21-4)

91830 Population-Based Projection of Vision-Related Disability in Australia 2020 - 2060: Prevalence, Causes, Associated Factors and Demand for Orientation and Mobility Services
Rogers K
Ophthalmic Epidemiology 2021; 0: 1-10 (IGR: 21-4)

91337 Changes in Performance of Glaucoma Surgeries 1994 through 2017 Based on Claims and Payment Data for United States Medicare Beneficiaries
Lee AY
Ophthalmology. Glaucoma 2021; 4: 463-471 (IGR: 21-4)

91830 Population-Based Projection of Vision-Related Disability in Australia 2020 - 2060: Prevalence, Causes, Associated Factors and Demand for Orientation and Mobility Services
Lung T
Ophthalmic Epidemiology 2021; 0: 1-10 (IGR: 21-4)

90973 Surgical Cancellations in Glaucoma Practice: Causes, Delays, and Effect on Patient Care and Revenue
Myers JS
Ophthalmology. Glaucoma 2021; 4: 427-432 (IGR: 21-4)

91126 Distribution and Predictors of Initial Glaucoma Care among Ophthalmologists and Optometrists: A Population-based Study
Whitehead M
Journal of Glaucoma 2021; 30: e300-e304 (IGR: 21-4)

91830 Population-Based Projection of Vision-Related Disability in Australia 2020 - 2060: Prevalence, Causes, Associated Factors and Demand for Orientation and Mobility Services
Shih S
Ophthalmic Epidemiology 2021; 0: 1-10 (IGR: 21-4)

91126 Distribution and Predictors of Initial Glaucoma Care among Ophthalmologists and Optometrists: A Population-based Study
Gill SS
Journal of Glaucoma 2021; 30: e300-e304 (IGR: 21-4)

90973 Surgical Cancellations in Glaucoma Practice: Causes, Delays, and Effect on Patient Care and Revenue
Razeghinejad R
Ophthalmology. Glaucoma 2021; 4: 427-432 (IGR: 21-4)

91126 Distribution and Predictors of Initial Glaucoma Care among Ophthalmologists and Optometrists: A Population-based Study
Campbell RJ
Journal of Glaucoma 2021; 30: e300-e304 (IGR: 21-4)

90973 Surgical Cancellations in Glaucoma Practice: Causes, Delays, and Effect on Patient Care and Revenue
Lee D
Ophthalmology. Glaucoma 2021; 4: 427-432 (IGR: 21-4)

91830 Population-Based Projection of Vision-Related Disability in Australia 2020 - 2060: Prevalence, Causes, Associated Factors and Demand for Orientation and Mobility Services
Huang-Lung J; Keay L
Ophthalmic Epidemiology 2021; 0: 1-10 (IGR: 21-4)

90973 Surgical Cancellations in Glaucoma Practice: Causes, Delays, and Effect on Patient Care and Revenue
Kolomeyer NN
Ophthalmology. Glaucoma 2021; 4: 427-432 (IGR: 21-4)

91830 Population-Based Projection of Vision-Related Disability in Australia 2020 - 2060: Prevalence, Causes, Associated Factors and Demand for Orientation and Mobility Services
Keay L
Ophthalmic Epidemiology 2021; 0: 1-10 (IGR: 21-4)

90973 Surgical Cancellations in Glaucoma Practice: Causes, Delays, and Effect on Patient Care and Revenue
Kolomeyer NN
Ophthalmology. Glaucoma 2021; 4: 427-432 (IGR: 21-4)

90089 The cost and quality of life impact of glaucoma in Tanzania: An observational study
Murdoch I
PLoS ONE 2020; 15: e0232796 (IGR: 21-3)

90617 Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness
Yong MH
Medical Journal of Malaysia 2020; 75: 342-348 (IGR: 21-3)

90098 Cost-Related Medication Nonadherence in a Nationally Representative US Population with Self-Reported Glaucoma
Gupta D
Ophthalmology. Glaucoma 2021; 4: 126-130 (IGR: 21-3)

90620 Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma
Yamada M
Journal of Medical Economics 2020; 23: 1293-1301 (IGR: 21-3)

90098 Cost-Related Medication Nonadherence in a Nationally Representative US Population with Self-Reported Glaucoma
Ehrlich JR
Ophthalmology. Glaucoma 2021; 4: 126-130 (IGR: 21-3)

90617 Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness
Che Hamzah J
Medical Journal of Malaysia 2020; 75: 342-348 (IGR: 21-3)

90089 The cost and quality of life impact of glaucoma in Tanzania: An observational study
Smith AF
PLoS ONE 2020; 15: e0232796 (IGR: 21-3)

90620 Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma
Nakano T
Journal of Medical Economics 2020; 23: 1293-1301 (IGR: 21-3)

90089 The cost and quality of life impact of glaucoma in Tanzania: An observational study
Baker H
PLoS ONE 2020; 15: e0232796 (IGR: 21-3)

90098 Cost-Related Medication Nonadherence in a Nationally Representative US Population with Self-Reported Glaucoma
Newman-Casey PA
Ophthalmology. Glaucoma 2021; 4: 126-130 (IGR: 21-3)

90620 Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma
Matsuda H
Journal of Medical Economics 2020; 23: 1293-1301 (IGR: 21-3)

90098 Cost-Related Medication Nonadherence in a Nationally Representative US Population with Self-Reported Glaucoma
Stagg B
Ophthalmology. Glaucoma 2021; 4: 126-130 (IGR: 21-3)

90620 Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma
Kim SW
Journal of Medical Economics 2020; 23: 1293-1301 (IGR: 21-3)

90089 The cost and quality of life impact of glaucoma in Tanzania: An observational study
Shilio B
PLoS ONE 2020; 15: e0232796 (IGR: 21-3)

90620 Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma
Takagi Y
Journal of Medical Economics 2020; 23: 1293-1301 (IGR: 21-3)

90089 The cost and quality of life impact of glaucoma in Tanzania: An observational study
Dhalla K
PLoS ONE 2020; 15: e0232796 (IGR: 21-3)

86574 Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
Bartlett VL
Journal of managed care & specialty pharmacy 2020; 26: 562-567 (IGR: 21-2)

86302 Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities
Serbin M
Journal of managed care & specialty pharmacy 2020; 26: 325-331 (IGR: 21-2)

86166 Health Economic Analysis in Glaucoma
Park I
Journal of Glaucoma 2020; 29: 304-311 (IGR: 21-2)

86349 Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study
Waterman H
British Journal of Ophthalmology 2020; 104: 1704-1709 (IGR: 21-2)

86785 Influence of Cost of Care and Adherence in Glaucoma Management: An Update
Meier-Gibbons F
Journal of Ophthalmology 2020; 2020: 5901537 (IGR: 21-2)

86784 The Use of Generic Medications for Glaucoma
Tatham AJ
Journal of Ophthalmology 2020; 2020: 1651265 (IGR: 21-2)

86349 Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study
Read S
British Journal of Ophthalmology 2020; 104: 1704-1709 (IGR: 21-2)

86785 Influence of Cost of Care and Adherence in Glaucoma Management: An Update
Töteberg-Harms M
Journal of Ophthalmology 2020; 2020: 5901537 (IGR: 21-2)

86302 Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities
Devine B
Journal of managed care & specialty pharmacy 2020; 26: 325-331 (IGR: 21-2)

86574 Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
Liu P
Journal of managed care & specialty pharmacy 2020; 26: 562-567 (IGR: 21-2)

86166 Health Economic Analysis in Glaucoma
Gale J; Skalicky SE
Journal of Glaucoma 2020; 29: 304-311 (IGR: 21-2)

86302 Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities
Campbell J
Journal of managed care & specialty pharmacy 2020; 26: 325-331 (IGR: 21-2)

86574 Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
Dhruva SS
Journal of managed care & specialty pharmacy 2020; 26: 562-567 (IGR: 21-2)

86349 Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study
Morgan JE; Gillespie D
British Journal of Ophthalmology 2020; 104: 1704-1709 (IGR: 21-2)

86574 Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
Shah ND
Journal of managed care & specialty pharmacy 2020; 26: 562-567 (IGR: 21-2)

86302 Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities
Basu A
Journal of managed care & specialty pharmacy 2020; 26: 325-331 (IGR: 21-2)

86574 Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
Bollinger KE
Journal of managed care & specialty pharmacy 2020; 26: 562-567 (IGR: 21-2)

86349 Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study
Nollett C
British Journal of Ophthalmology 2020; 104: 1704-1709 (IGR: 21-2)

86574 Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
Ross JS
Journal of managed care & specialty pharmacy 2020; 26: 562-567 (IGR: 21-2)

86349 Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study
Allen D; Weiss M; Anderson P
British Journal of Ophthalmology 2020; 104: 1704-1709 (IGR: 21-2)

84892 Association of sex with the global burden of glaucoma: an analysis from the global burden of disease study 2017
Ye X
Acta Ophthalmologica 2020; 0: (IGR: 21-1)

84906 Modeling the Pharmacotherapy Cost and Outcomes of Primary Open-Angle Glaucoma With Dry Eye
Tachkov K
Frontiers in public health 2019; 7: 363 (IGR: 21-1)

85129 Tilted Optic Disc Frequency in Myopia of Different Degree
Dervisevic E
Medicinski arhiv 2019; 73: 391-393 (IGR: 21-1)

84920 Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017
Yu L
PLoS ONE 2020; 15: e0227595 (IGR: 21-1)

84465 10-year trends in English primary care glaucoma prescribing
Hogg HDJ
Eye 2020; 34: 192-196 (IGR: 21-1)

84946 Minimally Invasive Glaucoma Surgery: A Budget Impact Analysis and Evaluation of Patients' Experiences, Preferences, and Values

Ontario health technology assessment series 2019; 19: 1-57 (IGR: 21-1)

85226 The Hub-and-Spoke Management of Glaucoma
Nuzzi R
Frontiers in neuroscience 2020; 14: 180 (IGR: 21-1)

84600 Taking the strain? Impact of glaucoma on patients' informal caregivers
McDonald L
Eye 2020; 34: 197-204 (IGR: 21-1)

84884 North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
Malvankar-Mehta MS
ClinicoEconomics and outcomes research : CEOR 2019; 11: 789-798 (IGR: 21-1)

84496 Care pathways for glaucoma detection and monitoring in the UK
Harper RA
Eye 2020; 34: 89-102 (IGR: 21-1)

84575 Improving Patient Access and Reducing Costs for Glaucoma with Integrated Hospital and Community Care: A Case Study from Australia
Ford BK
International journal of integrated care 2019; 19: 5 (IGR: 21-1)

84831 Comparing glaucoma medications and general demographics in a sample of glaucoma patients treated in private practice with nationwide registry data in Finland
Parkkari M
Acta Ophthalmologica 2019; 0: (IGR: 21-1)

85198 Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
Feldman RM
Clinical Ophthalmology 2020; 14: 729-739 (IGR: 21-1)

84205 Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
Bilger M
Applied health economics and health policy 2019; 17: 841-855 (IGR: 21-1)

84092 Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Albini TA
Ocular Immunology and Inflammation 2020; 28: 164-174 (IGR: 21-1)

85198 Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
Cioffi GA
Clinical Ophthalmology 2020; 14: 729-739 (IGR: 21-1)

84496 Care pathways for glaucoma detection and monitoring in the UK
Gunn PJG
Eye 2020; 34: 89-102 (IGR: 21-1)

84092 Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Rice JB
Ocular Immunology and Inflammation 2020; 28: 164-174 (IGR: 21-1)

84575 Improving Patient Access and Reducing Costs for Glaucoma with Integrated Hospital and Community Care: A Case Study from Australia
Angell B
International journal of integrated care 2019; 19: 5 (IGR: 21-1)

85226 The Hub-and-Spoke Management of Glaucoma
Marolo P
Frontiers in neuroscience 2020; 14: 180 (IGR: 21-1)

84600 Taking the strain? Impact of glaucoma on patients' informal caregivers
Turnbull P
Eye 2020; 34: 197-204 (IGR: 21-1)

84831 Comparing glaucoma medications and general demographics in a sample of glaucoma patients treated in private practice with nationwide registry data in Finland
Taipale J
Acta Ophthalmologica 2019; 0: (IGR: 21-1)

84920 Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017
Ding K
PLoS ONE 2020; 15: e0227595 (IGR: 21-1)

84205 Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
Wong TT
Applied health economics and health policy 2019; 17: 841-855 (IGR: 21-1)

84465 10-year trends in English primary care glaucoma prescribing
Connor A
Eye 2020; 34: 192-196 (IGR: 21-1)

84892 Association of sex with the global burden of glaucoma: an analysis from the global burden of disease study 2017
She X
Acta Ophthalmologica 2020; 0: (IGR: 21-1)

84884 North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
Feng L
ClinicoEconomics and outcomes research : CEOR 2019; 11: 789-798 (IGR: 21-1)

84906 Modeling the Pharmacotherapy Cost and Outcomes of Primary Open-Angle Glaucoma With Dry Eye
Vassilev A
Frontiers in public health 2019; 7: 363 (IGR: 21-1)

85129 Tilted Optic Disc Frequency in Myopia of Different Degree
Ibrisevic N
Medicinski arhiv 2019; 73: 391-393 (IGR: 21-1)

84575 Improving Patient Access and Reducing Costs for Glaucoma with Integrated Hospital and Community Care: A Case Study from Australia
Angell B
International journal of integrated care 2019; 19: 5 (IGR: 21-1)

84831 Comparing glaucoma medications and general demographics in a sample of glaucoma patients treated in private practice with nationwide registry data in Finland
Uusitalo H
Acta Ophthalmologica 2019; 0: (IGR: 21-1)

84920 Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017
Luo L
PLoS ONE 2020; 15: e0227595 (IGR: 21-1)

84884 North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
Hutnik CM
ClinicoEconomics and outcomes research : CEOR 2019; 11: 789-798 (IGR: 21-1)

84892 Association of sex with the global burden of glaucoma: an analysis from the global burden of disease study 2017
Shen L
Acta Ophthalmologica 2020; 0: (IGR: 21-1)

85198 Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
Liebmann JM
Clinical Ophthalmology 2020; 14: 729-739 (IGR: 21-1)

84205 Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
Lee JY
Applied health economics and health policy 2019; 17: 841-855 (IGR: 21-1)

84906 Modeling the Pharmacotherapy Cost and Outcomes of Primary Open-Angle Glaucoma With Dry Eye
Kostova S
Frontiers in public health 2019; 7: 363 (IGR: 21-1)

84575 Improving Patient Access and Reducing Costs for Glaucoma with Integrated Hospital and Community Care: A Case Study from Australia
Liew G
International journal of integrated care 2019; 19: 5 (IGR: 21-1)

84600 Taking the strain? Impact of glaucoma on patients' informal caregivers
Chang L
Eye 2020; 34: 197-204 (IGR: 21-1)

84092 Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
White AG
Ocular Immunology and Inflammation 2020; 28: 164-174 (IGR: 21-1)

84496 Care pathways for glaucoma detection and monitoring in the UK
Spry PGD
Eye 2020; 34: 89-102 (IGR: 21-1)

85226 The Hub-and-Spoke Management of Glaucoma
Nuzzi A
Frontiers in neuroscience 2020; 14: 180 (IGR: 21-1)

84600 Taking the strain? Impact of glaucoma on patients' informal caregivers
Crabb DP
Eye 2020; 34: 197-204 (IGR: 21-1)

84092 Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Johnson M
Ocular Immunology and Inflammation 2020; 28: 164-174 (IGR: 21-1)

84496 Care pathways for glaucoma detection and monitoring in the UK
Fenerty CH
Eye 2020; 34: 89-102 (IGR: 21-1)

84205 Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
Howard KL
Applied health economics and health policy 2019; 17: 841-855 (IGR: 21-1)

84575 Improving Patient Access and Reducing Costs for Glaucoma with Integrated Hospital and Community Care: A Case Study from Australia
White AJR
International journal of integrated care 2019; 19: 5 (IGR: 21-1)

85198 Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study
Weinreb RN
Clinical Ophthalmology 2020; 14: 729-739 (IGR: 21-1)

84920 Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017
Yu Z
PLoS ONE 2020; 15: e0227595 (IGR: 21-1)

84496 Care pathways for glaucoma detection and monitoring in the UK
Lawrenson JG
Eye 2020; 34: 89-102 (IGR: 21-1)

84575 Improving Patient Access and Reducing Costs for Glaucoma with Integrated Hospital and Community Care: A Case Study from Australia
Keay LJ
International journal of integrated care 2019; 19: 5 (IGR: 21-1)

84092 Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Reiff J
Ocular Immunology and Inflammation 2020; 28: 164-174 (IGR: 21-1)

84205 Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
Bundoc FG
Applied health economics and health policy 2019; 17: 841-855 (IGR: 21-1)

84092 Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Lima AF
Ocular Immunology and Inflammation 2020; 28: 164-174 (IGR: 21-1)

84205 Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
Lamoureux EL; Finkelstein EA
Applied health economics and health policy 2019; 17: 841-855 (IGR: 21-1)

84092 Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Bartels-Peculis L; Ciepielewska G; Nelson WW
Ocular Immunology and Inflammation 2020; 28: 164-174 (IGR: 21-1)

82814 Cost-Utility Analysis of Glaucoma Medication Adherence
Newman-Casey PA
Ophthalmology 2019; 0: (IGR: 20-4)

82201 Determining patient preferences in a glaucoma service: A discrete choice experiment
Lu TC
Clinical and Experimental Ophthalmology 2019; 47: 1146-1155 (IGR: 20-4)

82441 Burden, Positive Aspects, and Predictive Variables of Caregiving: A Study of Caregivers of Patients with Pediatric Glaucoma
Zhu Y
Journal of Ophthalmology 2019; 2019: 6980208 (IGR: 20-4)

82297 Journey to glaucoma care - trusting but uncertain and uninformed: a qualitative study
Lu TC
Clinical and Experimental Optometry 2020; 103: 484-489 (IGR: 20-4)

82080 Toward Better Health Outcomes in Rural and Under-served Areas: L. V. Prasad Eye Institute's Diagonal Model of Glaucoma Care
Choudhari NS
Ophthalmic Epidemiology 2019; 26: 420-429 (IGR: 20-4)

82201 Determining patient preferences in a glaucoma service: A discrete choice experiment
Lu TC
Clinical and Experimental Ophthalmology 2019; 47: 1146-1155 (IGR: 20-4)

82424 Auditing service delivery in glaucoma clinics using visual field records: a feasibility study
Kelly SR
BMJ open ophthalmology 2019; 4: e000352 (IGR: 20-4)

82651 Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement
Delgado MF
ClinicoEconomics and outcomes research : CEOR 2019; 11: 591-604 (IGR: 20-4)

82031 The cost burden of falls in people with glaucoma in National Health Service Hospital Trusts in the UK
McGinley P
Journal of Medical Economics 2020; 23: 106-112 (IGR: 20-4)

82297 Journey to glaucoma care - trusting but uncertain and uninformed: a qualitative study
Lu TC
Clinical and Experimental Optometry 2020; 103: 484-489 (IGR: 20-4)

82201 Determining patient preferences in a glaucoma service: A discrete choice experiment
Angell B
Clinical and Experimental Ophthalmology 2019; 47: 1146-1155 (IGR: 20-4)

82441 Burden, Positive Aspects, and Predictive Variables of Caregiving: A Study of Caregivers of Patients with Pediatric Glaucoma
Gao J
Journal of Ophthalmology 2019; 2019: 6980208 (IGR: 20-4)

82651 Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement
Abdelrahman AM
ClinicoEconomics and outcomes research : CEOR 2019; 11: 591-604 (IGR: 20-4)

82031 The cost burden of falls in people with glaucoma in National Health Service Hospital Trusts in the UK
Ansari E
Journal of Medical Economics 2020; 23: 106-112 (IGR: 20-4)

82080 Toward Better Health Outcomes in Rural and Under-served Areas: L. V. Prasad Eye Institute's Diagonal Model of Glaucoma Care
Mundhe G
Ophthalmic Epidemiology 2019; 26: 420-429 (IGR: 20-4)

82814 Cost-Utility Analysis of Glaucoma Medication Adherence
Salman M
Ophthalmology 2019; 0: (IGR: 20-4)

82297 Journey to glaucoma care - trusting but uncertain and uninformed: a qualitative study
Semsarian CR
Clinical and Experimental Optometry 2020; 103: 484-489 (IGR: 20-4)

82201 Determining patient preferences in a glaucoma service: A discrete choice experiment
Angell B
Clinical and Experimental Ophthalmology 2019; 47: 1146-1155 (IGR: 20-4)

82424 Auditing service delivery in glaucoma clinics using visual field records: a feasibility study
Bryan SR
BMJ open ophthalmology 2019; 4: e000352 (IGR: 20-4)

82201 Determining patient preferences in a glaucoma service: A discrete choice experiment
Dunn H
Clinical and Experimental Ophthalmology 2019; 47: 1146-1155 (IGR: 20-4)

82424 Auditing service delivery in glaucoma clinics using visual field records: a feasibility study
Sparrow JM
BMJ open ophthalmology 2019; 4: e000352 (IGR: 20-4)

82814 Cost-Utility Analysis of Glaucoma Medication Adherence
Lee PP
Ophthalmology 2019; 0: (IGR: 20-4)

82201 Determining patient preferences in a glaucoma service: A discrete choice experiment
Dunn H
Clinical and Experimental Ophthalmology 2019; 47: 1146-1155 (IGR: 20-4)

82031 The cost burden of falls in people with glaucoma in National Health Service Hospital Trusts in the UK
Sandhu H
Journal of Medical Economics 2020; 23: 106-112 (IGR: 20-4)

82651 Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement
Terahi M
ClinicoEconomics and outcomes research : CEOR 2019; 11: 591-604 (IGR: 20-4)

82080 Toward Better Health Outcomes in Rural and Under-served Areas: L. V. Prasad Eye Institute's Diagonal Model of Glaucoma Care
Khanna R
Ophthalmic Epidemiology 2019; 26: 420-429 (IGR: 20-4)

82297 Journey to glaucoma care - trusting but uncertain and uninformed: a qualitative study
White A
Clinical and Experimental Optometry 2020; 103: 484-489 (IGR: 20-4)

82441 Burden, Positive Aspects, and Predictive Variables of Caregiving: A Study of Caregivers of Patients with Pediatric Glaucoma
Li X
Journal of Ophthalmology 2019; 2019: 6980208 (IGR: 20-4)

82297 Journey to glaucoma care - trusting but uncertain and uninformed: a qualitative study
Dunn H
Clinical and Experimental Optometry 2020; 103: 484-489 (IGR: 20-4)

82031 The cost burden of falls in people with glaucoma in National Health Service Hospital Trusts in the UK
Dixon T
Journal of Medical Economics 2020; 23: 106-112 (IGR: 20-4)

82080 Toward Better Health Outcomes in Rural and Under-served Areas: L. V. Prasad Eye Institute's Diagonal Model of Glaucoma Care
Rathi V
Ophthalmic Epidemiology 2019; 26: 420-429 (IGR: 20-4)

82201 Determining patient preferences in a glaucoma service: A discrete choice experiment
Ford B
Clinical and Experimental Ophthalmology 2019; 47: 1146-1155 (IGR: 20-4)

82297 Journey to glaucoma care - trusting but uncertain and uninformed: a qualitative study
Dunn H
Clinical and Experimental Optometry 2020; 103: 484-489 (IGR: 20-4)

82424 Auditing service delivery in glaucoma clinics using visual field records: a feasibility study
Crabb DP
BMJ open ophthalmology 2019; 4: e000352 (IGR: 20-4)

82441 Burden, Positive Aspects, and Predictive Variables of Caregiving: A Study of Caregivers of Patients with Pediatric Glaucoma
Yang Q
Journal of Ophthalmology 2019; 2019: 6980208 (IGR: 20-4)

82201 Determining patient preferences in a glaucoma service: A discrete choice experiment
Ford B
Clinical and Experimental Ophthalmology 2019; 47: 1146-1155 (IGR: 20-4)

82814 Cost-Utility Analysis of Glaucoma Medication Adherence
Gatwood JD
Ophthalmology 2019; 0: (IGR: 20-4)

82651 Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement
Miro Quesada Woll JJ
ClinicoEconomics and outcomes research : CEOR 2019; 11: 591-604 (IGR: 20-4)

82080 Toward Better Health Outcomes in Rural and Under-served Areas: L. V. Prasad Eye Institute's Diagonal Model of Glaucoma Care
Garudadri CS
Ophthalmic Epidemiology 2019; 26: 420-429 (IGR: 20-4)

82651 Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement
Gil-Carrasco F
ClinicoEconomics and outcomes research : CEOR 2019; 11: 591-604 (IGR: 20-4)

82297 Journey to glaucoma care - trusting but uncertain and uninformed: a qualitative study
Angell B
Clinical and Experimental Optometry 2020; 103: 484-489 (IGR: 20-4)

82441 Burden, Positive Aspects, and Predictive Variables of Caregiving: A Study of Caregivers of Patients with Pediatric Glaucoma
Lian Y
Journal of Ophthalmology 2019; 2019: 6980208 (IGR: 20-4)

82201 Determining patient preferences in a glaucoma service: A discrete choice experiment
White A
Clinical and Experimental Ophthalmology 2019; 47: 1146-1155 (IGR: 20-4)

82297 Journey to glaucoma care - trusting but uncertain and uninformed: a qualitative study
Angell B
Clinical and Experimental Optometry 2020; 103: 484-489 (IGR: 20-4)

82651 Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement
Cook C
ClinicoEconomics and outcomes research : CEOR 2019; 11: 591-604 (IGR: 20-4)

82297 Journey to glaucoma care - trusting but uncertain and uninformed: a qualitative study
Ford B; Ford B
Clinical and Experimental Optometry 2020; 103: 484-489 (IGR: 20-4)

82201 Determining patient preferences in a glaucoma service: A discrete choice experiment
Keay L; Keay L
Clinical and Experimental Ophthalmology 2019; 47: 1146-1155 (IGR: 20-4)

82441 Burden, Positive Aspects, and Predictive Variables of Caregiving: A Study of Caregivers of Patients with Pediatric Glaucoma
Xiao H
Journal of Ophthalmology 2019; 2019: 6980208 (IGR: 20-4)

82651 Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement
Benharbit M
ClinicoEconomics and outcomes research : CEOR 2019; 11: 591-604 (IGR: 20-4)

82441 Burden, Positive Aspects, and Predictive Variables of Caregiving: A Study of Caregivers of Patients with Pediatric Glaucoma
Huang W
Journal of Ophthalmology 2019; 2019: 6980208 (IGR: 20-4)

82297 Journey to glaucoma care - trusting but uncertain and uninformed: a qualitative study
Keay L; Keay L
Clinical and Experimental Optometry 2020; 103: 484-489 (IGR: 20-4)

82651 Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement
Boisseau S; Chung E; Hadjiat Y; Gomes JA
ClinicoEconomics and outcomes research : CEOR 2019; 11: 591-604 (IGR: 20-4)

81091 Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights
Bartelt-Hofer J
PharmacoEconomics - open 2019; 0: (IGR: 20-3)

80674 The Cost and Economics of Endoscopic Cyclophotocoagulation in the United Kingdom: A Tertiary Center Experience
Ho H
Journal of Glaucoma 2019; 28: 563-567 (IGR: 20-3)

81033 Caregiver Burden in Primary Congenital Glaucoma
Kantipuly A
American Journal of Ophthalmology 2019; 205: 106-114 (IGR: 20-3)

80510 Epidemiological variations and trends in health burden of glaucoma worldwide
Wang W
Acta Ophthalmologica 2019; 97: e349-e355 (IGR: 20-3)

81057 Prevalence of treatment with glaucoma medication in Scotland, 2010-2017
Rotchford AP
British Journal of Ophthalmology 2019; 0: (IGR: 20-3)

80508 Evaluation of an Algorithm for Identifying Ocular Conditions in Electronic Health Record Data
Stein JD
JAMA ophthalmology 2019; 137: 491-497 (IGR: 20-3)

81466 Ophthalmic Care Utilization and Out-of-Pocket Expenditure in Iran: Kurdistan Eye Health and Economics Survey-2015
Mohammadi SF
Iranian journal of public health 2019; 48: 1301-1309 (IGR: 20-3)

80841 Overuse and Underuse of Visual Field Testing Over 15 Years
Ben-Artsi E
Journal of Glaucoma 2019; 28: 660-665 (IGR: 20-3)

81123 Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model
Tang J
The Lancet. Global health 2019; 7: e968-e978 (IGR: 20-3)

81465 Dynamic Monitoring and Control of Irreversible Chronic Diseases with Application to Glaucoma
Kazemian P
Production and operations management 2019; 28: 1082-1107 (IGR: 20-3)

81033 Caregiver Burden in Primary Congenital Glaucoma
Pillai MR
American Journal of Ophthalmology 2019; 205: 106-114 (IGR: 20-3)

80510 Epidemiological variations and trends in health burden of glaucoma worldwide
He M
Acta Ophthalmologica 2019; 97: e349-e355 (IGR: 20-3)

80841 Overuse and Underuse of Visual Field Testing Over 15 Years
Goldenfeld M
Journal of Glaucoma 2019; 28: 660-665 (IGR: 20-3)

81123 Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model
Liang Y
The Lancet. Global health 2019; 7: e968-e978 (IGR: 20-3)

80508 Evaluation of an Algorithm for Identifying Ocular Conditions in Electronic Health Record Data
Rahman M
JAMA ophthalmology 2019; 137: 491-497 (IGR: 20-3)

81465 Dynamic Monitoring and Control of Irreversible Chronic Diseases with Application to Glaucoma
Helm JE
Production and operations management 2019; 28: 1082-1107 (IGR: 20-3)

81466 Ophthalmic Care Utilization and Out-of-Pocket Expenditure in Iran: Kurdistan Eye Health and Economics Survey-2015
Alinia C
Iranian journal of public health 2019; 48: 1301-1309 (IGR: 20-3)

81057 Prevalence of treatment with glaucoma medication in Scotland, 2010-2017
Hughes J
British Journal of Ophthalmology 2019; 0: (IGR: 20-3)

81091 Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights
Ben-Debba L
PharmacoEconomics - open 2019; 0: (IGR: 20-3)

80674 The Cost and Economics of Endoscopic Cyclophotocoagulation in the United Kingdom: A Tertiary Center Experience
Ho J; Rodrigues I
Journal of Glaucoma 2019; 28: 563-567 (IGR: 20-3)

80841 Overuse and Underuse of Visual Field Testing Over 15 Years
Zehavi-Dorin T
Journal of Glaucoma 2019; 28: 660-665 (IGR: 20-3)

81466 Ophthalmic Care Utilization and Out-of-Pocket Expenditure in Iran: Kurdistan Eye Health and Economics Survey-2015
Ghaderi E
Iranian journal of public health 2019; 48: 1301-1309 (IGR: 20-3)

81123 Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model
O'Neill C
The Lancet. Global health 2019; 7: e968-e978 (IGR: 20-3)

80508 Evaluation of an Algorithm for Identifying Ocular Conditions in Electronic Health Record Data
Andrews C
JAMA ophthalmology 2019; 137: 491-497 (IGR: 20-3)

81057 Prevalence of treatment with glaucoma medication in Scotland, 2010-2017
Agarwal PK
British Journal of Ophthalmology 2019; 0: (IGR: 20-3)

81091 Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights
Flessa S
PharmacoEconomics - open 2019; 0: (IGR: 20-3)

81465 Dynamic Monitoring and Control of Irreversible Chronic Diseases with Application to Glaucoma
Lavieri MS
Production and operations management 2019; 28: 1082-1107 (IGR: 20-3)

81033 Caregiver Burden in Primary Congenital Glaucoma
Shroff S
American Journal of Ophthalmology 2019; 205: 106-114 (IGR: 20-3)

80510 Epidemiological variations and trends in health burden of glaucoma worldwide
Li Z
Acta Ophthalmologica 2019; 97: e349-e355 (IGR: 20-3)

80841 Overuse and Underuse of Visual Field Testing Over 15 Years
Cohen A
Journal of Glaucoma 2019; 28: 660-665 (IGR: 20-3)

81057 Prevalence of treatment with glaucoma medication in Scotland, 2010-2017
Tatham AJ
British Journal of Ophthalmology 2019; 0: (IGR: 20-3)

80508 Evaluation of an Algorithm for Identifying Ocular Conditions in Electronic Health Record Data
Ehrlich JR
JAMA ophthalmology 2019; 137: 491-497 (IGR: 20-3)

81466 Ophthalmic Care Utilization and Out-of-Pocket Expenditure in Iran: Kurdistan Eye Health and Economics Survey-2015
Lashay A
Iranian journal of public health 2019; 48: 1301-1309 (IGR: 20-3)

81033 Caregiver Burden in Primary Congenital Glaucoma
Khatiwala R
American Journal of Ophthalmology 2019; 205: 106-114 (IGR: 20-3)

80510 Epidemiological variations and trends in health burden of glaucoma worldwide
Huang W
Acta Ophthalmologica 2019; 97: e349-e355 (IGR: 20-3)

81123 Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model
Kee F
The Lancet. Global health 2019; 7: e968-e978 (IGR: 20-3)

80674 The Cost and Economics of Endoscopic Cyclophotocoagulation in the United Kingdom: A Tertiary Center Experience
Syrimi M
Journal of Glaucoma 2019; 28: 563-567 (IGR: 20-3)

81465 Dynamic Monitoring and Control of Irreversible Chronic Diseases with Application to Glaucoma
Stein JD
Production and operations management 2019; 28: 1082-1107 (IGR: 20-3)

81123 Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model
Jiang J
The Lancet. Global health 2019; 7: e968-e978 (IGR: 20-3)

81465 Dynamic Monitoring and Control of Irreversible Chronic Diseases with Application to Glaucoma
Van Oyen MP
Production and operations management 2019; 28: 1082-1107 (IGR: 20-3)

81466 Ophthalmic Care Utilization and Out-of-Pocket Expenditure in Iran: Kurdistan Eye Health and Economics Survey-2015
Jabbarvand M
Iranian journal of public health 2019; 48: 1301-1309 (IGR: 20-3)

80841 Overuse and Underuse of Visual Field Testing Over 15 Years
Porath A
Journal of Glaucoma 2019; 28: 660-665 (IGR: 20-3)

81033 Caregiver Burden in Primary Congenital Glaucoma
Raman GV
American Journal of Ophthalmology 2019; 205: 106-114 (IGR: 20-3)

80674 The Cost and Economics of Endoscopic Cyclophotocoagulation in the United Kingdom: A Tertiary Center Experience
Goyal S
Journal of Glaucoma 2019; 28: 563-567 (IGR: 20-3)

80508 Evaluation of an Algorithm for Identifying Ocular Conditions in Electronic Health Record Data
Kamat S
JAMA ophthalmology 2019; 137: 491-497 (IGR: 20-3)

80674 The Cost and Economics of Endoscopic Cyclophotocoagulation in the United Kingdom: A Tertiary Center Experience
Lim KS
Journal of Glaucoma 2019; 28: 563-567 (IGR: 20-3)

80508 Evaluation of an Algorithm for Identifying Ocular Conditions in Electronic Health Record Data
Shah M
JAMA ophthalmology 2019; 137: 491-497 (IGR: 20-3)

80841 Overuse and Underuse of Visual Field Testing Over 15 Years
Levkovitch-Verbin H
Journal of Glaucoma 2019; 28: 660-665 (IGR: 20-3)

81123 Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model
Congdon N
The Lancet. Global health 2019; 7: e968-e978 (IGR: 20-3)

81466 Ophthalmic Care Utilization and Out-of-Pocket Expenditure in Iran: Kurdistan Eye Health and Economics Survey-2015
Ashrafi E
Iranian journal of public health 2019; 48: 1301-1309 (IGR: 20-3)

81033 Caregiver Burden in Primary Congenital Glaucoma
Krishnadas SR
American Journal of Ophthalmology 2019; 205: 106-114 (IGR: 20-3)

80508 Evaluation of an Algorithm for Identifying Ocular Conditions in Electronic Health Record Data
Boese EA
JAMA ophthalmology 2019; 137: 491-497 (IGR: 20-3)

81033 Caregiver Burden in Primary Congenital Glaucoma
Lee Robin A
American Journal of Ophthalmology 2019; 205: 106-114 (IGR: 20-3)

81466 Ophthalmic Care Utilization and Out-of-Pocket Expenditure in Iran: Kurdistan Eye Health and Economics Survey-2015
Nourmohammadi N
Iranian journal of public health 2019; 48: 1301-1309 (IGR: 20-3)

81033 Caregiver Burden in Primary Congenital Glaucoma
Ehrlich JR
American Journal of Ophthalmology 2019; 205: 106-114 (IGR: 20-3)

81466 Ophthalmic Care Utilization and Out-of-Pocket Expenditure in Iran: Kurdistan Eye Health and Economics Survey-2015
Shahraz S
Iranian journal of public health 2019; 48: 1301-1309 (IGR: 20-3)

80508 Evaluation of an Algorithm for Identifying Ocular Conditions in Electronic Health Record Data
Woodward MA; Cowall J; Trager EH; Narayanaswamy P; Hanauer DA
JAMA ophthalmology 2019; 137: 491-497 (IGR: 20-3)

79738 Changes in Australian practice patterns for glaucoma management
Newman AR
Clinical and Experimental Ophthalmology 2019; 47: 571-580 (IGR: 20-2)

79389 Acute primary angle closure-treatment strategies, evidences and economical considerations
Chan PP
Eye 2019; 33: 110-119 (IGR: 20-2)

79934 Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada
Patel V
Journal of Medical Economics 2019; 22: 390-401 (IGR: 20-2)

80009 The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
Choi JA
Medicine 2019; 98: e14026 (IGR: 20-2)

80016 A Comparison of Resource Use and Costs of Caring for Patients With Exfoliation Syndrome Glaucoma Versus Primary Open-Angle Glaucoma
Rathi S
American Journal of Ophthalmology 2019; 200: 100-109 (IGR: 20-2)

79738 Changes in Australian practice patterns for glaucoma management
Andrew NH
Clinical and Experimental Ophthalmology 2019; 47: 571-580 (IGR: 20-2)

80009 The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
Song LD
Medicine 2019; 98: e14026 (IGR: 20-2)

79934 Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada
Ahmed I
Journal of Medical Economics 2019; 22: 390-401 (IGR: 20-2)

80016 A Comparison of Resource Use and Costs of Caring for Patients With Exfoliation Syndrome Glaucoma Versus Primary Open-Angle Glaucoma
Andrews C
American Journal of Ophthalmology 2019; 200: 100-109 (IGR: 20-2)

79389 Acute primary angle closure-treatment strategies, evidences and economical considerations
Pang JC
Eye 2019; 33: 110-119 (IGR: 20-2)

79738 Changes in Australian practice patterns for glaucoma management
Andrew NH
Clinical and Experimental Ophthalmology 2019; 47: 571-580 (IGR: 20-2)

80009 The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
Choi S
Medicine 2019; 98: e14026 (IGR: 20-2)

79934 Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada
Podbielski D
Journal of Medical Economics 2019; 22: 390-401 (IGR: 20-2)

80016 A Comparison of Resource Use and Costs of Caring for Patients With Exfoliation Syndrome Glaucoma Versus Primary Open-Angle Glaucoma
Greenfield DS
American Journal of Ophthalmology 2019; 200: 100-109 (IGR: 20-2)

79389 Acute primary angle closure-treatment strategies, evidences and economical considerations
Tham CC
Eye 2019; 33: 110-119 (IGR: 20-2)

79934 Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada
Falvey H
Journal of Medical Economics 2019; 22: 390-401 (IGR: 20-2)

80009 The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
Park SM
Medicine 2019; 98: e14026 (IGR: 20-2)

80016 A Comparison of Resource Use and Costs of Caring for Patients With Exfoliation Syndrome Glaucoma Versus Primary Open-Angle Glaucoma
Stein JD
American Journal of Ophthalmology 2019; 200: 100-109 (IGR: 20-2)

79934 Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada
Murray J
Journal of Medical Economics 2019; 22: 390-401 (IGR: 20-2)

80009 The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
Kwon JW
Medicine 2019; 98: e14026 (IGR: 20-2)

79934 Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada
Goeree R
Journal of Medical Economics 2019; 22: 390-401 (IGR: 20-2)

80009 The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
Jee D
Medicine 2019; 98: e14026 (IGR: 20-2)

78322 Potential Savings from Visit Reduction of Continuous Intraocular Pressure Monitoring
Dong J
Journal of Current Glaucoma Practice 2018; 12: 59-63 (IGR: 20-1)

79264 Influence of glaucoma surgery on visual function: a clinical cohort study and meta-analysis
Junoy Montolio FG
Acta Ophthalmologica 2019; 97: 193-199 (IGR: 20-1)

78878 Healthcare Utilization by Glaucoma Patients in a Team Care Model
Damento GM
Seminars in Ophthalmology 2018; 33: 829-837 (IGR: 20-1)

78829 Direct costs of glaucoma: Relationship between cost and severity of the disease
Real JP
Chronic illness 2018; 0: 1742395318803660 (IGR: 20-1)

79080 The Current Status of Glaucoma and Glaucoma Care in Sub-Saharan Africa
Kyari F
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 375-386 (IGR: 20-1)

78447 A cost minimisation analysis comparing iStent accompanying cataract surgery and selective laser trabeculoplasty versus topical glaucoma medications in a public healthcare setting in New Zealand
Ngan K
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 2181-2189 (IGR: 20-1)

79286 A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery
Zhao PY
JAMA ophthalmology 2018; 136: 1271-1279 (IGR: 20-1)

78447 A cost minimisation analysis comparing iStent accompanying cataract surgery and selective laser trabeculoplasty versus topical glaucoma medications in a public healthcare setting in New Zealand
Fraser E
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 2181-2189 (IGR: 20-1)

79264 Influence of glaucoma surgery on visual function: a clinical cohort study and meta-analysis
Müskens RPHM
Acta Ophthalmologica 2019; 97: 193-199 (IGR: 20-1)

79286 A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery
Rahmathullah R
JAMA ophthalmology 2018; 136: 1271-1279 (IGR: 20-1)

79080 The Current Status of Glaucoma and Glaucoma Care in Sub-Saharan Africa
Adekoya B
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 375-386 (IGR: 20-1)

78322 Potential Savings from Visit Reduction of Continuous Intraocular Pressure Monitoring
Syed ZA
Journal of Current Glaucoma Practice 2018; 12: 59-63 (IGR: 20-1)

78878 Healthcare Utilization by Glaucoma Patients in a Team Care Model
Winkler NS
Seminars in Ophthalmology 2018; 33: 829-837 (IGR: 20-1)

78829 Direct costs of glaucoma: Relationship between cost and severity of the disease
Lafuente MC
Chronic illness 2018; 0: 1742395318803660 (IGR: 20-1)

79286 A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery
Stagg BC
JAMA ophthalmology 2018; 136: 1271-1279 (IGR: 20-1)

78322 Potential Savings from Visit Reduction of Continuous Intraocular Pressure Monitoring
Fan K
Journal of Current Glaucoma Practice 2018; 12: 59-63 (IGR: 20-1)

78447 A cost minimisation analysis comparing iStent accompanying cataract surgery and selective laser trabeculoplasty versus topical glaucoma medications in a public healthcare setting in New Zealand
Buller S
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 2181-2189 (IGR: 20-1)

78878 Healthcare Utilization by Glaucoma Patients in a Team Care Model
Hodge DO
Seminars in Ophthalmology 2018; 33: 829-837 (IGR: 20-1)

78829 Direct costs of glaucoma: Relationship between cost and severity of the disease
Palma SD
Chronic illness 2018; 0: 1742395318803660 (IGR: 20-1)

79264 Influence of glaucoma surgery on visual function: a clinical cohort study and meta-analysis
Jansonius NM
Acta Ophthalmologica 2019; 97: 193-199 (IGR: 20-1)

79080 The Current Status of Glaucoma and Glaucoma Care in Sub-Saharan Africa
Abdull MM
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 375-386 (IGR: 20-1)

78829 Direct costs of glaucoma: Relationship between cost and severity of the disease
Tártara LI
Chronic illness 2018; 0: 1742395318803660 (IGR: 20-1)

78878 Healthcare Utilization by Glaucoma Patients in a Team Care Model
Khanna SS
Seminars in Ophthalmology 2018; 33: 829-837 (IGR: 20-1)

78447 A cost minimisation analysis comparing iStent accompanying cataract surgery and selective laser trabeculoplasty versus topical glaucoma medications in a public healthcare setting in New Zealand
Buller A
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 2181-2189 (IGR: 20-1)

79286 A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery
Almobarak F
JAMA ophthalmology 2018; 136: 1271-1279 (IGR: 20-1)

78322 Potential Savings from Visit Reduction of Continuous Intraocular Pressure Monitoring
Yahya AF
Journal of Current Glaucoma Practice 2018; 12: 59-63 (IGR: 20-1)

79080 The Current Status of Glaucoma and Glaucoma Care in Sub-Saharan Africa
Mohammed AS
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 375-386 (IGR: 20-1)

78878 Healthcare Utilization by Glaucoma Patients in a Team Care Model
Khanna CL
Seminars in Ophthalmology 2018; 33: 829-837 (IGR: 20-1)

79080 The Current Status of Glaucoma and Glaucoma Care in Sub-Saharan Africa
Garba F
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 375-386 (IGR: 20-1)

78322 Potential Savings from Visit Reduction of Continuous Intraocular Pressure Monitoring
Melki SA
Journal of Current Glaucoma Practice 2018; 12: 59-63 (IGR: 20-1)

79286 A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery
Edward DP; Robin AL; Stein JD
JAMA ophthalmology 2018; 136: 1271-1279 (IGR: 20-1)

77714 Changes in Ocular Hypotensive Drug Usage for Glaucoma Treatment After Cataract Surgery: A Nationwide Population-based Study in Taiwan
Chang PY
Journal of Glaucoma 2018; 27: 600-605 (IGR: 19-4)

78076 Glaucoma in inpatient care in Germany in 2015
Hahn U
Ophthalmologe 2019; 116: 542-552 (IGR: 19-4)

78269 Eye care utilisation in Newfoundland and Labrador: access barriers and vision health outcomes
Lee EY
Canadian Journal of Ophthalmology 2018; 53: 342-348 (IGR: 19-4)

78222 Glaucoma Control Strategies in Sub-Saharan Africa: A Review of the Clinical and Health Economic Evidence
Smith AF
Ophthalmic Epidemiology 2018; 25: 419-435 (IGR: 19-4)

77714 Changes in Ocular Hypotensive Drug Usage for Glaucoma Treatment After Cataract Surgery: A Nationwide Population-based Study in Taiwan
Wang JY
Journal of Glaucoma 2018; 27: 600-605 (IGR: 19-4)

78076 Glaucoma in inpatient care in Germany in 2015
Kretz F
Ophthalmologe 2019; 116: 542-552 (IGR: 19-4)

78222 Glaucoma Control Strategies in Sub-Saharan Africa: A Review of the Clinical and Health Economic Evidence
Negretti G
Ophthalmic Epidemiology 2018; 25: 419-435 (IGR: 19-4)

78269 Eye care utilisation in Newfoundland and Labrador: access barriers and vision health outcomes
Cui K; Trope GE
Canadian Journal of Ophthalmology 2018; 53: 342-348 (IGR: 19-4)

78222 Glaucoma Control Strategies in Sub-Saharan Africa: A Review of the Clinical and Health Economic Evidence
Mascaro A
Ophthalmic Epidemiology 2018; 25: 419-435 (IGR: 19-4)

77714 Changes in Ocular Hypotensive Drug Usage for Glaucoma Treatment After Cataract Surgery: A Nationwide Population-based Study in Taiwan
Chang SW
Journal of Glaucoma 2018; 27: 600-605 (IGR: 19-4)

78076 Glaucoma in inpatient care in Germany in 2015
Koch J
Ophthalmologe 2019; 116: 542-552 (IGR: 19-4)

78269 Eye care utilisation in Newfoundland and Labrador: access barriers and vision health outcomes
Buys YM
Canadian Journal of Ophthalmology 2018; 53: 342-348 (IGR: 19-4)

78222 Glaucoma Control Strategies in Sub-Saharan Africa: A Review of the Clinical and Health Economic Evidence
Bokre D
Ophthalmic Epidemiology 2018; 25: 419-435 (IGR: 19-4)

77714 Changes in Ocular Hypotensive Drug Usage for Glaucoma Treatment After Cataract Surgery: A Nationwide Population-based Study in Taiwan
Chang YC
Journal of Glaucoma 2018; 27: 600-605 (IGR: 19-4)

78269 Eye care utilisation in Newfoundland and Labrador: access barriers and vision health outcomes
Chan CH
Canadian Journal of Ophthalmology 2018; 53: 342-348 (IGR: 19-4)

78222 Glaucoma Control Strategies in Sub-Saharan Africa: A Review of the Clinical and Health Economic Evidence
Baker H; Dhalla K
Ophthalmic Epidemiology 2018; 25: 419-435 (IGR: 19-4)

78269 Eye care utilisation in Newfoundland and Labrador: access barriers and vision health outcomes
Thavorn K; Jin YP
Canadian Journal of Ophthalmology 2018; 53: 342-348 (IGR: 19-4)

78222 Glaucoma Control Strategies in Sub-Saharan Africa: A Review of the Clinical and Health Economic Evidence
Murdoch IE
Ophthalmic Epidemiology 2018; 25: 419-435 (IGR: 19-4)

76974 Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults
Sharafeldin N
British Journal of Ophthalmology 2018; 0: (IGR: 19-3)

77309 Health technology assessment: A primer for ophthalmology
Murphy A
European Journal of Ophthalmology 2018; 28: 358-364 (IGR: 19-3)

76301 A Systematic Evaluation of State Laws Governing Optometric Glaucoma Management in the United States Upto 2015
Chodnicki K
Journal of Glaucoma 2018; 27: 233-238 (IGR: 19-3)

76890 Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario
Popovic M
Canadian Journal of Ophthalmology 2018; 53: 173-187 (IGR: 19-3)

76898 Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012
Khan AM
BMC Health Services Research 2018; 18: 273 (IGR: 19-3)

77102 The Association of Socioeconomic Status with Severity of Glaucoma and the Impacts of Both Factors on the Costs of Glaucoma Medications: A Cross-Sectional Study in West Bengal, India
Chakravarti T
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 442-451 (IGR: 19-3)

76301 A Systematic Evaluation of State Laws Governing Optometric Glaucoma Management in the United States Upto 2015
Kalarn S
Journal of Glaucoma 2018; 27: 233-238 (IGR: 19-3)

76890 Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario
Chan C
Canadian Journal of Ophthalmology 2018; 53: 173-187 (IGR: 19-3)

77309 Health technology assessment: A primer for ophthalmology
McElnea E
European Journal of Ophthalmology 2018; 28: 358-364 (IGR: 19-3)

76898 Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012
Trope GE
BMC Health Services Research 2018; 18: 273 (IGR: 19-3)

76974 Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults
Kawaguchi A
British Journal of Ophthalmology 2018; 0: (IGR: 19-3)

76301 A Systematic Evaluation of State Laws Governing Optometric Glaucoma Management in the United States Upto 2015
Kalarn S; Quinn L
Journal of Glaucoma 2018; 27: 233-238 (IGR: 19-3)

76898 Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012
Wedge R
BMC Health Services Research 2018; 18: 273 (IGR: 19-3)

77309 Health technology assessment: A primer for ophthalmology
Byrne S
European Journal of Ophthalmology 2018; 28: 358-364 (IGR: 19-3)

76890 Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario
Lattanzio N
Canadian Journal of Ophthalmology 2018; 53: 173-187 (IGR: 19-3)

76974 Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults
Sundaram A
British Journal of Ophthalmology 2018; 0: (IGR: 19-3)

76890 Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario
El-Defrawy S
Canadian Journal of Ophthalmology 2018; 53: 173-187 (IGR: 19-3)

76898 Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012
Buys YM
BMC Health Services Research 2018; 18: 273 (IGR: 19-3)

76890 Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario
El-Defrawy S
Canadian Journal of Ophthalmology 2018; 53: 173-187 (IGR: 19-3)

76301 A Systematic Evaluation of State Laws Governing Optometric Glaucoma Management in the United States Upto 2015
Jampel H
Journal of Glaucoma 2018; 27: 233-238 (IGR: 19-3)

76974 Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults
Campbell S
British Journal of Ophthalmology 2018; 0: (IGR: 19-3)

76898 Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012
El-Defrawy S; El-Defrawy S
BMC Health Services Research 2018; 18: 273 (IGR: 19-3)

76974 Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults
Rudnisky C
British Journal of Ophthalmology 2018; 0: (IGR: 19-3)

76301 A Systematic Evaluation of State Laws Governing Optometric Glaucoma Management in the United States Upto 2015
Saeedi O
Journal of Glaucoma 2018; 27: 233-238 (IGR: 19-3)

76890 Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario
Schlenker MB
Canadian Journal of Ophthalmology 2018; 53: 173-187 (IGR: 19-3)

76974 Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults
Weis E
British Journal of Ophthalmology 2018; 0: (IGR: 19-3)

76898 Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012
Chen Q
BMC Health Services Research 2018; 18: 273 (IGR: 19-3)

76974 Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults
Tennant MTS
British Journal of Ophthalmology 2018; 0: (IGR: 19-3)

76898 Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012
Jin YP
BMC Health Services Research 2018; 18: 273 (IGR: 19-3)

76974 Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults
Damji KF
British Journal of Ophthalmology 2018; 0: (IGR: 19-3)

75590 Shared Cared for Stable Glaucoma Patients: Economic Benefits and Patient-centered Outcomes of a Feasibility Trial
Goh D
Journal of Glaucoma 2018; 27: 170-175 (IGR: 19-2)

75437 Patient-Physician Communication on Medication Cost during Glaucoma Visits
Slota C
Optometry and Vision Science 2017; 94: 1095-1101 (IGR: 19-2)

75619 Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity
Batra R; Sharma HE
Seminars in Ophthalmology 2017; 0: 1-6 (IGR: 19-2)

75437 Patient-Physician Communication on Medication Cost during Glaucoma Visits
Davis SA
Optometry and Vision Science 2017; 94: 1095-1101 (IGR: 19-2)

75590 Shared Cared for Stable Glaucoma Patients: Economic Benefits and Patient-centered Outcomes of a Feasibility Trial
de Korne DF
Journal of Glaucoma 2018; 27: 170-175 (IGR: 19-2)

75437 Patient-Physician Communication on Medication Cost during Glaucoma Visits
Blalock SJ
Optometry and Vision Science 2017; 94: 1095-1101 (IGR: 19-2)

75590 Shared Cared for Stable Glaucoma Patients: Economic Benefits and Patient-centered Outcomes of a Feasibility Trial
Ho H
Journal of Glaucoma 2018; 27: 170-175 (IGR: 19-2)

75619 Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity
Elaraoud I
Seminars in Ophthalmology 2017; 0: 1-6 (IGR: 19-2)

75590 Shared Cared for Stable Glaucoma Patients: Economic Benefits and Patient-centered Outcomes of a Feasibility Trial
Mathur R
Journal of Glaucoma 2018; 27: 170-175 (IGR: 19-2)

75437 Patient-Physician Communication on Medication Cost during Glaucoma Visits
Carpenter DM
Optometry and Vision Science 2017; 94: 1095-1101 (IGR: 19-2)

75619 Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity
Mohamed S
Seminars in Ophthalmology 2017; 0: 1-6 (IGR: 19-2)

75437 Patient-Physician Communication on Medication Cost during Glaucoma Visits
Muir KW
Optometry and Vision Science 2017; 94: 1095-1101 (IGR: 19-2)

75590 Shared Cared for Stable Glaucoma Patients: Economic Benefits and Patient-centered Outcomes of a Feasibility Trial
Chakraborty B; Van Hai N
Journal of Glaucoma 2018; 27: 170-175 (IGR: 19-2)

75437 Patient-Physician Communication on Medication Cost during Glaucoma Visits
Robin AL
Optometry and Vision Science 2017; 94: 1095-1101 (IGR: 19-2)

75590 Shared Cared for Stable Glaucoma Patients: Economic Benefits and Patient-centered Outcomes of a Feasibility Trial
Wai C
Journal of Glaucoma 2018; 27: 170-175 (IGR: 19-2)

75437 Patient-Physician Communication on Medication Cost during Glaucoma Visits
Sleath B
Optometry and Vision Science 2017; 94: 1095-1101 (IGR: 19-2)

75590 Shared Cared for Stable Glaucoma Patients: Economic Benefits and Patient-centered Outcomes of a Feasibility Trial
Perera S; Aung T; Wong TY; Lamoureux EL
Journal of Glaucoma 2018; 27: 170-175 (IGR: 19-2)

74087 Prospective study of glaucoma referrals across Europe: are we using resources wisely?
Founti P
British Journal of Ophthalmology 2018; 102: 329-337 (IGR: 19-1)

74272 Cost-effectiveness of Phacoemulsification Versus Combined Phacotrabeculectomy for Treating Primary Angle Closure Glaucoma
Chan PP
Journal of Glaucoma 2017; 26: 911-922 (IGR: 19-1)

74248 Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization
Trese MGJ
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 591-597 (IGR: 19-1)

74087 Prospective study of glaucoma referrals across Europe: are we using resources wisely?
Topouzis F
British Journal of Ophthalmology 2018; 102: 329-337 (IGR: 19-1)

74272 Cost-effectiveness of Phacoemulsification Versus Combined Phacotrabeculectomy for Treating Primary Angle Closure Glaucoma
Li EY
Journal of Glaucoma 2017; 26: 911-922 (IGR: 19-1)

74248 Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization
Lewis AW; Blachley TS
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 591-597 (IGR: 19-1)

74272 Cost-effectiveness of Phacoemulsification Versus Combined Phacotrabeculectomy for Treating Primary Angle Closure Glaucoma
Tsoi KKF
Journal of Glaucoma 2017; 26: 911-922 (IGR: 19-1)

74087 Prospective study of glaucoma referrals across Europe: are we using resources wisely?
Holló G
British Journal of Ophthalmology 2018; 102: 329-337 (IGR: 19-1)

74272 Cost-effectiveness of Phacoemulsification Versus Combined Phacotrabeculectomy for Treating Primary Angle Closure Glaucoma
Kwong YY
Journal of Glaucoma 2017; 26: 911-922 (IGR: 19-1)

74248 Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization
Stein JD
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 591-597 (IGR: 19-1)

74087 Prospective study of glaucoma referrals across Europe: are we using resources wisely?
Cvenkel B
British Journal of Ophthalmology 2018; 102: 329-337 (IGR: 19-1)

74272 Cost-effectiveness of Phacoemulsification Versus Combined Phacotrabeculectomy for Treating Primary Angle Closure Glaucoma
Tham CC
Journal of Glaucoma 2017; 26: 911-922 (IGR: 19-1)

74087 Prospective study of glaucoma referrals across Europe: are we using resources wisely?
Iester M
British Journal of Ophthalmology 2018; 102: 329-337 (IGR: 19-1)

74248 Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization
Moroi SE
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 591-597 (IGR: 19-1)

74087 Prospective study of glaucoma referrals across Europe: are we using resources wisely?
Haidich AB; Kóthy P; Kiana A; Kolokotroni D; Viswanathan AC
British Journal of Ophthalmology 2018; 102: 329-337 (IGR: 19-1)

72841 Cost-effectiveness and cost utility of community screening for glaucoma in urban India
John D
Public Health 2017; 148: 37-48 (IGR: 18-4)

72996 Cost-comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medications only for intraocular pressure control for patients with open-angle glaucoma
Berdahl JP
Journal of Medical Economics 2017; 20: 760-766 (IGR: 18-4)

72743 Nonmedical Out-of-Pocket Patient and Companion Expenditures Associated With Glaucoma Care
Schehlein EM
Journal of Glaucoma 2017; 26: 343-348 (IGR: 18-4)

72825 Detection and prevention of blindness in patients with glaucoma is a socio-economical challenge
Kolko M
Ugeskrift for Laeger 2017; 179: (IGR: 18-4)

72624 Proposing new indicators for glaucoma healthcare service
Liang YB
Eye and vision (London, England) 2017; 4: 6 (IGR: 18-4)

72743 Nonmedical Out-of-Pocket Patient and Companion Expenditures Associated With Glaucoma Care
Im LT
Journal of Glaucoma 2017; 26: 343-348 (IGR: 18-4)

72841 Cost-effectiveness and cost utility of community screening for glaucoma in urban India
Parikh R
Public Health 2017; 148: 37-48 (IGR: 18-4)

72624 Proposing new indicators for glaucoma healthcare service
Zhang Y
Eye and vision (London, England) 2017; 4: 6 (IGR: 18-4)

72996 Cost-comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medications only for intraocular pressure control for patients with open-angle glaucoma
Khatana AK
Journal of Medical Economics 2017; 20: 760-766 (IGR: 18-4)

72624 Proposing new indicators for glaucoma healthcare service
Musch DC
Eye and vision (London, England) 2017; 4: 6 (IGR: 18-4)

72996 Cost-comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medications only for intraocular pressure control for patients with open-angle glaucoma
Katz LJ
Journal of Medical Economics 2017; 20: 760-766 (IGR: 18-4)

72743 Nonmedical Out-of-Pocket Patient and Companion Expenditures Associated With Glaucoma Care
Robin AL
Journal of Glaucoma 2017; 26: 343-348 (IGR: 18-4)

72624 Proposing new indicators for glaucoma healthcare service
Congdon N
Eye and vision (London, England) 2017; 4: 6 (IGR: 18-4)

72743 Nonmedical Out-of-Pocket Patient and Companion Expenditures Associated With Glaucoma Care
Onukwugha E
Journal of Glaucoma 2017; 26: 343-348 (IGR: 18-4)

72996 Cost-comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medications only for intraocular pressure control for patients with open-angle glaucoma
Herndon L; Layton AJ
Journal of Medical Economics 2017; 20: 760-766 (IGR: 18-4)

72743 Nonmedical Out-of-Pocket Patient and Companion Expenditures Associated With Glaucoma Care
Saeedi OJ
Journal of Glaucoma 2017; 26: 343-348 (IGR: 18-4)

72996 Cost-comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medications only for intraocular pressure control for patients with open-angle glaucoma
Yu TM; Bauer MJ; Cantor LB
Journal of Medical Economics 2017; 20: 760-766 (IGR: 18-4)

71610 A cross-sectional study on compliance with topical glaucoma medication and its associated socioeconomic burden for a Chinese population
Lui MH
International Journal of Ophthalmology 2017; 10: 293-299 (IGR: 18-3)

71527 Cost-effectiveness of glaucoma management with monotherapy medications in Egypt
El-Khamery AA
Journal of advanced pharmaceutical technology & research 2017; 8: 25-28 (IGR: 18-3)

71585 Cost and detection rate of glaucoma screening with imaging devices in a primary care center
Anton A; Fallon M
Clinical Ophthalmology 2017; 11: 337-346 (IGR: 18-3)

71610 A cross-sectional study on compliance with topical glaucoma medication and its associated socioeconomic burden for a Chinese population
Lam JC
International Journal of Ophthalmology 2017; 10: 293-299 (IGR: 18-3)

71585 Cost and detection rate of glaucoma screening with imaging devices in a primary care center
Cots F
Clinical Ophthalmology 2017; 11: 337-346 (IGR: 18-3)

71610 A cross-sectional study on compliance with topical glaucoma medication and its associated socioeconomic burden for a Chinese population
Kwong YL
International Journal of Ophthalmology 2017; 10: 293-299 (IGR: 18-3)

71527 Cost-effectiveness of glaucoma management with monotherapy medications in Egypt
Swify HE; Mohamed AI
Journal of advanced pharmaceutical technology & research 2017; 8: 25-28 (IGR: 18-3)

71585 Cost and detection rate of glaucoma screening with imaging devices in a primary care center
Sebastian MA
Clinical Ophthalmology 2017; 11: 337-346 (IGR: 18-3)

71610 A cross-sectional study on compliance with topical glaucoma medication and its associated socioeconomic burden for a Chinese population
Wong TS; Cheung PL
International Journal of Ophthalmology 2017; 10: 293-299 (IGR: 18-3)

71585 Cost and detection rate of glaucoma screening with imaging devices in a primary care center
Morilla-Grasa A; Mojal S
Clinical Ophthalmology 2017; 11: 337-346 (IGR: 18-3)

71610 A cross-sectional study on compliance with topical glaucoma medication and its associated socioeconomic burden for a Chinese population
Lai SS; Yuen PL
International Journal of Ophthalmology 2017; 10: 293-299 (IGR: 18-3)

71585 Cost and detection rate of glaucoma screening with imaging devices in a primary care center
Castells X
Clinical Ophthalmology 2017; 11: 337-346 (IGR: 18-3)

71610 A cross-sectional study on compliance with topical glaucoma medication and its associated socioeconomic burden for a Chinese population
Lam WY; Chan HY; Wong YF; Lai JS; Shih KC
International Journal of Ophthalmology 2017; 10: 293-299 (IGR: 18-3)

70851 Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity
Guedes RA
Medicine 2016; 95: e5745 (IGR: 18-2)

70409 More frequent, more costly? Health economic modelling aspects of monitoring glaucoma patients in England
Boodhna T
BMC Health Services Research 2016; 16: 611 (IGR: 18-2)

70121 Effectiveness of UK optometric enhanced eye care services: a realist review of the literature
Baker H
Ophthalmic and Physiological Optics 2016; 36: 545-557 (IGR: 18-2)

70512 Increasing healthcare costs: can we influence the costs of glaucoma care?
Töteberg-Harms M
Current Opinions in Ophthalmology 2017; 28: 127-132 (IGR: 18-2)

70373 The Visual Function Questionnaire: Utility Index: Does It Measure Glaucoma-related Preference-based Status?
Goh RL
Journal of Glaucoma 2016; 25: 822-829 (IGR: 18-2)

70624 Cost of glaucoma treatment in a developing country over a 5-year period
Lazcano-Gomez G
Medicine 2016; 95: e5341 (IGR: 18-2)

70512 Increasing healthcare costs: can we influence the costs of glaucoma care?
Berlin MS
Current Opinions in Ophthalmology 2017; 28: 127-132 (IGR: 18-2)

70409 More frequent, more costly? Health economic modelling aspects of monitoring glaucoma patients in England
Crabb DP
BMC Health Services Research 2016; 16: 611 (IGR: 18-2)

70121 Effectiveness of UK optometric enhanced eye care services: a realist review of the literature
Ratnarajan G
Ophthalmic and Physiological Optics 2016; 36: 545-557 (IGR: 18-2)

70851 Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity
Guedes VM
Medicine 2016; 95: e5745 (IGR: 18-2)

70624 Cost of glaucoma treatment in a developing country over a 5-year period
Ramos-Cadena ML
Medicine 2016; 95: e5341 (IGR: 18-2)

70373 The Visual Function Questionnaire: Utility Index: Does It Measure Glaucoma-related Preference-based Status?
Fenwick E
Journal of Glaucoma 2016; 25: 822-829 (IGR: 18-2)

70121 Effectiveness of UK optometric enhanced eye care services: a realist review of the literature
Harper RA
Ophthalmic and Physiological Optics 2016; 36: 545-557 (IGR: 18-2)

70373 The Visual Function Questionnaire: Utility Index: Does It Measure Glaucoma-related Preference-based Status?
Skalicky SE
Journal of Glaucoma 2016; 25: 822-829 (IGR: 18-2)

70851 Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity
Gomes CE
Medicine 2016; 95: e5745 (IGR: 18-2)

70624 Cost of glaucoma treatment in a developing country over a 5-year period
Torres-Tamayo M
Medicine 2016; 95: e5341 (IGR: 18-2)

70512 Increasing healthcare costs: can we influence the costs of glaucoma care?
Meier-Gibbons F
Current Opinions in Ophthalmology 2017; 28: 127-132 (IGR: 18-2)

70851 Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity
Chaoubah A
Medicine 2016; 95: e5745 (IGR: 18-2)

70624 Cost of glaucoma treatment in a developing country over a 5-year period
Hernandez de Oteyza A
Medicine 2016; 95: e5341 (IGR: 18-2)

70121 Effectiveness of UK optometric enhanced eye care services: a realist review of the literature
Edgar DF
Ophthalmic and Physiological Optics 2016; 36: 545-557 (IGR: 18-2)

70624 Cost of glaucoma treatment in a developing country over a 5-year period
Turati-Acosta M
Medicine 2016; 95: e5341 (IGR: 18-2)

70121 Effectiveness of UK optometric enhanced eye care services: a realist review of the literature
Lawrenson JG
Ophthalmic and Physiological Optics 2016; 36: 545-557 (IGR: 18-2)

70624 Cost of glaucoma treatment in a developing country over a 5-year period
Jimenez-Román J
Medicine 2016; 95: e5341 (IGR: 18-2)

68947 Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma
Schultz NM
American Journal of Ophthalmology 2016; 168: 78-85 (IGR: 18-1)

69350 Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities
Ocansey S
BMC Health Services Research 2016; 16: 282 (IGR: 18-1)

68973 Geographical variation in glaucoma prescribing trends in England 2008-2012: an observational ecological study
Heng JS
BMJ open 2016; 6: e010429 (IGR: 18-1)

69184 Drug-prescribing patterns among optometrists and nonophthalmologist physicians at a tertiary care centre in Kingston, Ontario
Johnson D; El-Defrawy SR
Canadian Journal of Ophthalmology 2016; 51: 168-173 (IGR: 18-1)

68947 Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma
Wong WB
American Journal of Ophthalmology 2016; 168: 78-85 (IGR: 18-1)

68973 Geographical variation in glaucoma prescribing trends in England 2008-2012: an observational ecological study
Wormald R
BMJ open 2016; 6: e010429 (IGR: 18-1)

69350 Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities
Kyei S
BMC Health Services Research 2016; 16: 282 (IGR: 18-1)

68973 Geographical variation in glaucoma prescribing trends in England 2008-2012: an observational ecological study
Khaw PT
BMJ open 2016; 6: e010429 (IGR: 18-1)

69184 Drug-prescribing patterns among optometrists and nonophthalmologist physicians at a tertiary care centre in Kingston, Ontario
Hollands S
Canadian Journal of Ophthalmology 2016; 51: 168-173 (IGR: 18-1)

68947 Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma
Coleman AL
American Journal of Ophthalmology 2016; 168: 78-85 (IGR: 18-1)

69350 Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities
Diafo A
BMC Health Services Research 2016; 16: 282 (IGR: 18-1)

69184 Drug-prescribing patterns among optometrists and nonophthalmologist physicians at a tertiary care centre in Kingston, Ontario
Hurst J
Canadian Journal of Ophthalmology 2016; 51: 168-173 (IGR: 18-1)

69350 Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities
Darfor KN
BMC Health Services Research 2016; 16: 282 (IGR: 18-1)

68947 Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma
Malone DC
American Journal of Ophthalmology 2016; 168: 78-85 (IGR: 18-1)

69350 Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities
Boadi-Kusi SB
BMC Health Services Research 2016; 16: 282 (IGR: 18-1)

69184 Drug-prescribing patterns among optometrists and nonophthalmologist physicians at a tertiary care centre in Kingston, Ontario
Law C
Canadian Journal of Ophthalmology 2016; 51: 168-173 (IGR: 18-1)

69350 Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities
Aglobitse PB
BMC Health Services Research 2016; 16: 282 (IGR: 18-1)

69184 Drug-prescribing patterns among optometrists and nonophthalmologist physicians at a tertiary care centre in Kingston, Ontario
Li C; Baxter S; Campbell Ede L; Campbell RJ
Canadian Journal of Ophthalmology 2016; 51: 168-173 (IGR: 18-1)

66936 Treatment of ocular hypertension: is it cost effective?
Tuulonen A
Current Opinions in Ophthalmology 2016; 27: 89-93 (IGR: 17-4)

67296 The Economic Burden of Childhood Glaucoma
Liu D; Huang L; Mukkamala L; Khouri AS
Journal of Glaucoma 2016; 25: 790-797 (IGR: 17-4)

66596 Self-reported Function, Health Resource Use, and Total Health Care Costs Among Medicare Beneficiaries With Glaucoma
Prager AJ
JAMA ophthalmology 2016; 134: 357-365 (IGR: 17-3)

65900 Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma
Queen JH
American Journal of Ophthalmology 2016; 163: 70-74.e1 (IGR: 17-3)

66610 Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D
Blumberg DM
JAMA ophthalmology 2016; 134: 212-220 (IGR: 17-3)

66505 The Evolution of Teleophthalmology Programs in the United Kingdom: Beyond Diabetic Retinopathy Screening
Sim DA
Journal of diabetes science and technology 2016; 10: 308-317 (IGR: 17-3)

66362 Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective
Hernández R
British Journal of Ophthalmology 2016; 100: 1263-1268 (IGR: 17-3)

65900 Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma
Feldman RM
American Journal of Ophthalmology 2016; 163: 70-74.e1 (IGR: 17-3)

66505 The Evolution of Teleophthalmology Programs in the United Kingdom: Beyond Diabetic Retinopathy Screening
Mitry D
Journal of diabetes science and technology 2016; 10: 308-317 (IGR: 17-3)

66596 Self-reported Function, Health Resource Use, and Total Health Care Costs Among Medicare Beneficiaries With Glaucoma
Liebmann JM
JAMA ophthalmology 2016; 134: 357-365 (IGR: 17-3)

66610 Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D
Prager AJ
JAMA ophthalmology 2016; 134: 212-220 (IGR: 17-3)

66362 Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective
Burr JM
British Journal of Ophthalmology 2016; 100: 1263-1268 (IGR: 17-3)

66610 Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D
Liebmann JM
JAMA ophthalmology 2016; 134: 212-220 (IGR: 17-3)

66362 Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective
Vale L
British Journal of Ophthalmology 2016; 100: 1263-1268 (IGR: 17-3)

66505 The Evolution of Teleophthalmology Programs in the United Kingdom: Beyond Diabetic Retinopathy Screening
Alexander P
Journal of diabetes science and technology 2016; 10: 308-317 (IGR: 17-3)

65900 Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma
Lee DA
American Journal of Ophthalmology 2016; 163: 70-74.e1 (IGR: 17-3)

66596 Self-reported Function, Health Resource Use, and Total Health Care Costs Among Medicare Beneficiaries With Glaucoma
Cioffi GA
JAMA ophthalmology 2016; 134: 357-365 (IGR: 17-3)

66362 Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective
Azuara-Blanco A
British Journal of Ophthalmology 2016; 100: 1263-1268 (IGR: 17-3)

66505 The Evolution of Teleophthalmology Programs in the United Kingdom: Beyond Diabetic Retinopathy Screening
Mapani A
Journal of diabetes science and technology 2016; 10: 308-317 (IGR: 17-3)

66596 Self-reported Function, Health Resource Use, and Total Health Care Costs Among Medicare Beneficiaries With Glaucoma
Blumberg DM
JAMA ophthalmology 2016; 134: 357-365 (IGR: 17-3)

66505 The Evolution of Teleophthalmology Programs in the United Kingdom: Beyond Diabetic Retinopathy Screening
Goverdhan S
Journal of diabetes science and technology 2016; 10: 308-317 (IGR: 17-3)

66362 Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective
Cook JA; Banister K
British Journal of Ophthalmology 2016; 100: 1263-1268 (IGR: 17-3)

66505 The Evolution of Teleophthalmology Programs in the United Kingdom: Beyond Diabetic Retinopathy Screening
Aslam T; Tufail A
Journal of diabetes science and technology 2016; 10: 308-317 (IGR: 17-3)

66362 Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective
Tuulonen A; Ryan M
British Journal of Ophthalmology 2016; 100: 1263-1268 (IGR: 17-3)

66505 The Evolution of Teleophthalmology Programs in the United Kingdom: Beyond Diabetic Retinopathy Screening
Egan CA; Keane PA
Journal of diabetes science and technology 2016; 10: 308-317 (IGR: 17-3)

66362 Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective

British Journal of Ophthalmology 2016; 100: 1263-1268 (IGR: 17-3)

61672 Volumetric and cost evaluation study of glaucoma medical therapy
Banga HK
International journal of applied & basic medical research 2015; 5: 96-99 (IGR: 17-1)

61744 Comparison of United States and canadian glaucoma medication costs and price change from 2006 to 2013
Schlenker MB
Journal of Ophthalmology 2015; 2015: 547960 (IGR: 17-1)

61359 Use of Various Glaucoma Surgeries and Procedures in Medicare Beneficiaries from 1994 to 2012
Arora KS
Ophthalmology 2015; 122: 1615-1624 (IGR: 17-1)

61669 Cost Analysis of Commonly used Combination of Drugs in Primary Open Angle Glaucoma
Kumbar SK
Journal of clinical and diagnostic research : JCDR 2015; 9: FC05-8 (IGR: 17-1)

61429 Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D
Blumberg DM
JAMA ophthalmology 2015; 133: 985-996 (IGR: 17-1)

61303 Trends in Glaucoma Medication Expenditures under Universal Health Coverage: A National Population-Based Longitudinal Survey in Taiwan
Chiu SL
Journal of Ophthalmology 2015; 2015: 243401 (IGR: 17-1)

61429 Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D
Prager AJ
JAMA ophthalmology 2015; 133: 985-996 (IGR: 17-1)

61669 Cost Analysis of Commonly used Combination of Drugs in Primary Open Angle Glaucoma
Mirje M
Journal of clinical and diagnostic research : JCDR 2015; 9: FC05-8 (IGR: 17-1)

61303 Trends in Glaucoma Medication Expenditures under Universal Health Coverage: A National Population-Based Longitudinal Survey in Taiwan
Chu CL
Journal of Ophthalmology 2015; 2015: 243401 (IGR: 17-1)

61359 Use of Various Glaucoma Surgeries and Procedures in Medicare Beneficiaries from 1994 to 2012
Robin AL
Ophthalmology 2015; 122: 1615-1624 (IGR: 17-1)

61672 Volumetric and cost evaluation study of glaucoma medical therapy
Gupta AK
International journal of applied & basic medical research 2015; 5: 96-99 (IGR: 17-1)

61744 Comparison of United States and canadian glaucoma medication costs and price change from 2006 to 2013
Trope GE
Journal of Ophthalmology 2015; 2015: 547960 (IGR: 17-1)

61669 Cost Analysis of Commonly used Combination of Drugs in Primary Open Angle Glaucoma
Moharir G
Journal of clinical and diagnostic research : JCDR 2015; 9: FC05-8 (IGR: 17-1)

61359 Use of Various Glaucoma Surgeries and Procedures in Medicare Beneficiaries from 1994 to 2012
Corcoran KJ
Ophthalmology 2015; 122: 1615-1624 (IGR: 17-1)

61429 Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D
Liebmann JM
JAMA ophthalmology 2015; 133: 985-996 (IGR: 17-1)

61672 Volumetric and cost evaluation study of glaucoma medical therapy
Singh G
International journal of applied & basic medical research 2015; 5: 96-99 (IGR: 17-1)

61744 Comparison of United States and canadian glaucoma medication costs and price change from 2006 to 2013
Buys YM
Journal of Ophthalmology 2015; 2015: 547960 (IGR: 17-1)

61303 Trends in Glaucoma Medication Expenditures under Universal Health Coverage: A National Population-Based Longitudinal Survey in Taiwan
Muo CH
Journal of Ophthalmology 2015; 2015: 243401 (IGR: 17-1)

61359 Use of Various Glaucoma Surgeries and Procedures in Medicare Beneficiaries from 1994 to 2012
Corcoran SL
Ophthalmology 2015; 122: 1615-1624 (IGR: 17-1)

61669 Cost Analysis of Commonly used Combination of Drugs in Primary Open Angle Glaucoma
Bharatha A
Journal of clinical and diagnostic research : JCDR 2015; 9: FC05-8 (IGR: 17-1)

61429 Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D
Cioffi GA
JAMA ophthalmology 2015; 133: 985-996 (IGR: 17-1)

61303 Trends in Glaucoma Medication Expenditures under Universal Health Coverage: A National Population-Based Longitudinal Survey in Taiwan
Chen CL; Lan SJ
Journal of Ophthalmology 2015; 2015: 243401 (IGR: 17-1)

61359 Use of Various Glaucoma Surgeries and Procedures in Medicare Beneficiaries from 1994 to 2012
Ramulu PY
Ophthalmology 2015; 122: 1615-1624 (IGR: 17-1)

61429 Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D
De Moraes CG
JAMA ophthalmology 2015; 133: 985-996 (IGR: 17-1)

60129 Improving patient access to prevent sight loss: ophthalmic electronic referrals and communication (Scotland)
Khan AA
Public Health 2015; 129: 117-123 (IGR: 16-4)

60337 A Quantitative Analysis of the Relationship between Medicare Payment and Service Volume for Glaucoma Procedures from 2005 through 2009
Gong D
Ophthalmology 2015; 122: 1049-1055 (IGR: 16-4)

60594 Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment
Kaplan RI
JAMA ophthalmology 2015; 0: (IGR: 16-4)

60087 The impact of lack of government-insured routine eye examinations on the incidence of self-reported glaucoma, cataracts, and vision loss
Chan CH
Investigative Ophthalmology and Visual Science 2014; 55: 8544-8549 (IGR: 16-4)

60122 Different strategies and cost-effectiveness in the treatment of primary open angle glaucoma
Ting NS
ClinicoEconomics and outcomes research : CEOR 2014; 6: 523-530 (IGR: 16-4)

60251 A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension
Natt NK
Indian Journal of Ophthalmology 2014; 62: 1136-1140 (IGR: 16-4)

60478 Socioeconomics of long-term glaucoma therapy in India
Nayak B
Indian Journal of Ophthalmology 2015; 63: 20-24 (IGR: 16-4)

60394 Incremental Healthcare Service Utilization for Open-angle Glaucoma: A Population-based Study
Chung SD; Ho J
Journal of Glaucoma 2015; 24: e116-e120 (IGR: 16-4)

60478 Socioeconomics of long-term glaucoma therapy in India
Gupta S
Indian Journal of Ophthalmology 2015; 63: 20-24 (IGR: 16-4)

60251 A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension
Gupta A
Indian Journal of Ophthalmology 2014; 62: 1136-1140 (IGR: 16-4)

60087 The impact of lack of government-insured routine eye examinations on the incidence of self-reported glaucoma, cataracts, and vision loss
Trope GE
Investigative Ophthalmology and Visual Science 2014; 55: 8544-8549 (IGR: 16-4)

60594 Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment
De Moraes CG
JAMA ophthalmology 2015; 0: (IGR: 16-4)

60129 Improving patient access to prevent sight loss: ophthalmic electronic referrals and communication (Scotland)
Mustafa MZ
Public Health 2015; 129: 117-123 (IGR: 16-4)

60337 A Quantitative Analysis of the Relationship between Medicare Payment and Service Volume for Glaucoma Procedures from 2005 through 2009
Jun L
Ophthalmology 2015; 122: 1049-1055 (IGR: 16-4)

60122 Different strategies and cost-effectiveness in the treatment of primary open angle glaucoma
Li Yim JF
ClinicoEconomics and outcomes research : CEOR 2014; 6: 523-530 (IGR: 16-4)

60594 Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment
Cioffi GA
JAMA ophthalmology 2015; 0: (IGR: 16-4)

60122 Different strategies and cost-effectiveness in the treatment of primary open angle glaucoma
Ng JY
ClinicoEconomics and outcomes research : CEOR 2014; 6: 523-530 (IGR: 16-4)

60251 A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension
Singh G
Indian Journal of Ophthalmology 2014; 62: 1136-1140 (IGR: 16-4)

60129 Improving patient access to prevent sight loss: ophthalmic electronic referrals and communication (Scotland)
Sanders R
Public Health 2015; 129: 117-123 (IGR: 16-4)

60337 A Quantitative Analysis of the Relationship between Medicare Payment and Service Volume for Glaucoma Procedures from 2005 through 2009
Tsai JC
Ophthalmology 2015; 122: 1049-1055 (IGR: 16-4)

60394 Incremental Healthcare Service Utilization for Open-angle Glaucoma: A Population-based Study
Lin HC
Journal of Glaucoma 2015; 24: e116-e120 (IGR: 16-4)

60478 Socioeconomics of long-term glaucoma therapy in India
Kumar G
Indian Journal of Ophthalmology 2015; 63: 20-24 (IGR: 16-4)

60087 The impact of lack of government-insured routine eye examinations on the incidence of self-reported glaucoma, cataracts, and vision loss
Badley EM; Buys YM
Investigative Ophthalmology and Visual Science 2014; 55: 8544-8549 (IGR: 16-4)

60594 Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment
Al-Aswad LA
JAMA ophthalmology 2015; 0: (IGR: 16-4)

60478 Socioeconomics of long-term glaucoma therapy in India
Dada T
Indian Journal of Ophthalmology 2015; 63: 20-24 (IGR: 16-4)

60394 Incremental Healthcare Service Utilization for Open-angle Glaucoma: A Population-based Study
Kao LT
Journal of Glaucoma 2015; 24: e116-e120 (IGR: 16-4)

60251 A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension
Singh T
Indian Journal of Ophthalmology 2014; 62: 1136-1140 (IGR: 16-4)

60478 Socioeconomics of long-term glaucoma therapy in India
Gupta V
Indian Journal of Ophthalmology 2015; 63: 20-24 (IGR: 16-4)

60394 Incremental Healthcare Service Utilization for Open-angle Glaucoma: A Population-based Study
Tsai MC
Journal of Glaucoma 2015; 24: e116-e120 (IGR: 16-4)

60087 The impact of lack of government-insured routine eye examinations on the incidence of self-reported glaucoma, cataracts, and vision loss
Jin YP
Investigative Ophthalmology and Visual Science 2014; 55: 8544-8549 (IGR: 16-4)

60594 Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment
Blumberg DM
JAMA ophthalmology 2015; 0: (IGR: 16-4)

60478 Socioeconomics of long-term glaucoma therapy in India
Sihota R
Indian Journal of Ophthalmology 2015; 63: 20-24 (IGR: 16-4)

59342 The Peterborough Scheme for Community Specialist Optometrists in Glaucoma: Results of 4 Years of a Two-Tiered Community-Based Assessment and Follow-up Service
Roberts HW; Rughani K; Syam P; Dhingra S; Ramirez-Florez S
Current Eye Research 2014; 0: 1-7 (IGR: 16-3)

58859 Economic analysis of the Ex-PRESS miniature glaucoma device versus trabeculectomy
Patel HY; Wagschal LD; Trope GE; Buys YM
Journal of Glaucoma 2014; 23: 385-390 (IGR: 16-3)

58996 Burden of undetected and untreated glaucoma in the United States
Shaikh Y; Yu F; Coleman AL
American Journal of Ophthalmology 2014; 158: 1121-1129.e1 (IGR: 16-3)

58907 Does government assistance improve utilization of eye care services by low-income individuals?
Hong CJ; Trope GE; Buys YM; Robinson BE; Jin YP
Canadian Journal of Ophthalmology 2014; 49: 320-325 (IGR: 16-3)

59132 Ophthalmic digital image transfer: benefits to triage, patient care and resource
Goudie C; Lunt D; Reid S; Sanders R
Ophthalmic and Physiological Optics 2014; 34: 628-635 (IGR: 16-3)

59589 Addressing inequalities in eye health with subsidies and increased fees for General Ophthalmic Services in socio-economically deprived communities: a sensitivity analysis
Shickle D; Todkill D; Chisholm C; Rughani S; Griffin M; Cassels-Brown A; May H; Slade SV; Davey CJ
Public Health 2015; 129: 131-137 (IGR: 16-3)

59150 Global Burden of Eye and Vision Disease as Reflected in the Cochrane Database of Systematic Reviews
Boyers LN; Karimkhani C; Hilton J; Richheimer W; Dellavalle RP
JAMA ophthalmology 2015; 133: 25-31 (IGR: 16-3)

59163 The short-sighted perspective of long-term eye health-care
Jamous KF; Kalloniatis M; Boon MY; Jalbert I; Zangerl B
Clinical and Experimental Optometry 2014; 97: 565-567 (IGR: 16-3)

59131 Drug Utilization Study in Ophthalmology Out-patient Department of a Medical College in India
Banerjee I; Bhadury T; Sengupta T; Roy D
Annals of medical and health sciences research 2014; 4: 667-670 (IGR: 16-3)

59564 Evaluating the validity of clinical codes to identify cataract and glaucoma in the UK Clinical Practice Research Datalink
Kang EM; Pinheiro SP; Hammad TA; Abou-Ali A
Pharmacoepidemiology and Drug Safety 2015; 24: 38-44 (IGR: 16-3)

57473 Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis
Tham YC; Li X; Wong TY; Quigley HA; Aung T; Cheng CY
Ophthalmology 2014; 121: 2081-2090 (IGR: 16-2)

56991 Visual impairment registration: evaluation of agreement among ophthalmologists
Guerin E; Bouliotis G; King A
Eye 2014; 28: 808-813 (IGR: 16-2)

57254 Glaucoma prescribing trends in England 2000 to 2012
Connor AJ; Fraser SG
Eye 2014; 28: 863-869 (IGR: 16-2)

57057 Trends over time and regional variations in the rate of laser trabeculoplasty in the Medicare population
Jampel HD; Cassard SD; Friedman DS; Shekhawat NS; Whiteside-De Vos J; Quigley HA; Gower EW
JAMA ophthalmology 2014; 132: 685-690 (IGR: 16-2)

56934 Financial return-on-investment of ophthalmic interventions: a new paradigm
Brown MM; Brown GC; Lieske HB; Lieske PA
Current Opinions in Ophthalmology 2014; 25: 171-176 (IGR: 16-2)

57223 Macroeconomic costs of eye diseases
Hirneiß C; Kampik A; Neubauer AS
Ophthalmologe 2014; 111: 420-427 (IGR: 16-2)

55519 Increase in examinations for cataracts, glaucoma, diabetic retinopathy and age-related macular degeneration : Comparative cross-sectional study between 2010 and 1997 in ophthalmological practices
Bertram B; Gante C; Hilgers RD
Ophthalmologe 2014; 111: 757-764 (IGR: 15-4)

55497 Vision problems are a leading source of modifiable health expenditures
Rein DB
Investigative Ophthalmology and Visual Science 2013; 54: ORSF18-22 (IGR: 15-4)

55490 The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension
Van Gestel A; Schouten JS; Beckers HJ; Severens JL; Hendrikse F; Webers CA
Acta Ophthalmologica 2014; 92: 513-523 (IGR: 15-4)

54878 Screening for glaucoma: U.S. Preventive Services Task Force Recommendation Statement
Moyer VA
Annals of Internal Medicine 2013; 159: 484-489 (IGR: 15-3)

54771 Global rates of glaucoma surgery
Mansouri K; Medeiros FA; Weinreb RN
Graefe's Archive for Clinical and Experimental Ophthalmology 2013; 251: 2609-2615 (IGR: 15-3)

54434 Topical glaucoma therapy cost in Mexico
Lazcano-Gomez G; Hernandez-Oteyza A; Iriarte-Barbosa MJ; Hernandez-Garciadiego C
International Ophthalmology 2014; 34: 241-249 (IGR: 15-3)

54460 An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%
Wong WB; Patel VD; Kowalski JW; Schwartz G
Current Medical Research and Opinion 2013; 29: 1191-1200 (IGR: 15-3)

54628 Identification of persons with incident ocular diseases using health care claims databases
Stein JD; Blachley TS; Musch DC
American Journal of Ophthalmology 2013; 156: 1169-1175 (IGR: 15-3)

53983 Projected Cost Comparison of Trabectome, iStent, and Endoscopic Cyclophotocoagulation Versus Glaucoma Medication in the Ontario Health Insurance Plan
Iordanous Y; Kent JS; Hutnik CM; Malvankar-Mehta MS
Journal of Glaucoma 2014; 23: e112-e118 (IGR: 15-2)

53918 The Cost of Glaucoma Care Provided to Medicare Beneficiaries from 2002 to 2009
Quigley HA; Cassard SD; Gower EW; Ramulu PY; Jampel HD; Friedman DS
Ophthalmology 2013; 120: 2249-2257 (IGR: 15-2)

53821 Managed care implications of age-related ocular conditions
Cardarelli WJ; Smith RA
American Journal of Managed Care 2013; 19: s85-91 (IGR: 15-2)

53557 Direct healthcare costs of glaucoma treatment
Rahman MQ; Beard SM; Discombe R; Sharma R; Montgomery DM
British Journal of Ophthalmology 2013; 97: 720-724 (IGR: 15-2)

53628 Direct cost and predictive factors for treatment in patients with ocular hypertension or early, moderate and advanced primary open-angle glaucoma: the CoGIS study in Germany
Lorenz K; Wolfram C; Breitscheidel L; Shlaen M; Verboven Y; Pfeiffer N
Graefe's Archive for Clinical and Experimental Ophthalmology 2013; 251: 2019-2028 (IGR: 15-2)

53618 Comparison of resource utilization in the treatment of open-angle glaucoma between two cities in Finland: is more better?
Hagman J
Acta Ophthalmologica 2013; 91: 1-47 (IGR: 15-2)

53577 Cost-effectiveness of treating normal tension glaucoma
Li EY; Tham CC; Chi SC; Lam DS
Investigative Ophthalmology and Visual Science 2013; 54: 3394-3399 (IGR: 15-2)

52440 Accounting for Costs, QALYs, and Capacity Constraints: Using Discrete-Event Simulation to Evaluate Alternative Service Delivery and Organizational Scenarios for Hospital-Based Glaucoma Services
Crane GJ; Kymes SM; Hiller JE; Casson R; Martin A; Karnon JD
Medical decision making : an international journal of the Society for Medical Decision Making 2013; 33: 986-997 (IGR: 15-1)

52895 Caregiver burden assessment in primary congenital glaucoma
Dada T; Aggarwal A; Bali SJ; Wadhwani M; Tinwala S; Sagar R
European Journal of Ophthalmology 2013; 23: 324-328 (IGR: 15-1)

52619 Why a successful task substitution in glaucoma care could not be transferred from a hospital setting to a primary care setting: a qualitative study
Holtzer-Goor KM; Plochg T; Lemij HG; van Sprundel E; Koopmanschap MA; Klazinga NS
Implementation science : IS 2013; 8: 14 (IGR: 15-1)

52769 Trends in inpatient treatment in ophthalmology in Germany
Finger RP; Köberlein-Neu J; Gass P; Holz FG; Bertram B
Ophthalmologe 2013; 110: 224-229 (IGR: 15-1)

52657 Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany
Thelen U; Schnober D; Schölzel S; Kristoffersen MS; Nelson LA; Stewart JA; Stewart WC
International Journal of Ophthalmology 2013; 6: 155-159 (IGR: 15-1)

52803 Glaucoma costs in Denmark in treatment naive patients
Olsen J; Berdeaux G; Skov J
Acta Ophthalmologica 2013; 91: 25-31 (IGR: 15-1)

52715 The impact of glaucoma referral refinement criteria on referral to, and first-visit discharge rates from, the hospital eye service: the Health Innovation & Education Cluster (HIEC) Glaucoma Pathways project
Ratnarajan G; Newsom W; French K; Kean J; Chang L; Parker M; Garway-Heath DF; Bourne RR
Ophthalmic and Physiological Optics 2013; 33: 183-189 (IGR: 15-1)

52735 Glaucoma management in Sweden -- results from a nationwide survey
Lindén C; Bengtsson B; Alm A; Calissendorff B; Eckerlund I; Heijl A
Acta Ophthalmologica 2013; 91: 20-24 (IGR: 15-1)

51801 Medical service encounters and payments associated with topical adjunctive therapy use of timolol for glaucoma
Schmier JK; Covert DW; Lau EC
Clinical Drug Investigation 2012; 32: 835-842 (IGR: 14-4)

51927 Comparison of Acquisition Costs of Surgical Supplies in Different Health Care Systems for Cataract and Glaucoma Procedures
Valentine J; Zurakowski D; Ayyala RS
Journal of Glaucoma 2014; 23: 355-359 (IGR: 14-4)

51949 Racial disparities in the use of ancillary testing to evaluate individuals with open-angle glaucoma
Stein JD; Talwar N; Laverne AM; Nan B; Lichter PR
Archives of Ophthalmology 2012; 130: 1579-1588 (IGR: 14-4)

51999 Economic burden of glaucoma in Rivers State, Nigeria
Adio AO; Onua AA
Clinical Ophthalmology 2012; 6: 2023-2031 (IGR: 14-4)

51948 Vision Insurance, Eye Care Visits, and Vision Impairment Among Working-Age Adults in the United States
Li YJ; Xirasagar S; Pumkam C; Krishnaswamy M; Bennett CL
Archives of Ophthalmology 2012; 0: 1-8 (IGR: 14-4)

51720 Medical record validation of self-reported eye diseases and eye care utilization among older adults
MacLennan PA; McGwin G; Searcey K; Owsley C
Current Eye Research 2013; 38: 1-8 (IGR: 14-4)

51760 The effect of changes in referral behaviour following NICE guideline publication on agreement of examination findings between professionals in an established glaucoma referral refinement pathway: the Health Innovation & Education Cluster (HIEC) Glaucoma P
Ratnarajan G; Newsom W; French K; Kean J; Chang L; Parker M; Garway-Heath DF; Bourne RR
British Journal of Ophthalmology 2013; 97: 210-214 (IGR: 14-4)

51238 Trabeculectomy versus Canaloplasty - Utility and Cost-Effectiveness Analysis
Brüggemann A; Müller M
Klinische Monatsblätter für Augenheilkunde 2012; 229: 1118-1123 (IGR: 14-3)

50688 Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches
Orme M; Collins S; Loftus J
Journal of Glaucoma 2012; 21: 433-449 (IGR: 14-3)

50964 Longitudinal trends in resource use in an incident cohort of open-angle glaucoma patients: resource use in open-angle glaucoma
Stein JD; Niziol LM; Musch DC; Lee PP; Kotak SV; Peters CM; Kymes SM
American Journal of Ophthalmology 2012; 154: 452-459.e2 (IGR: 14-3)

51010 Surgical Output and Clinic Burden of Glaucoma in Lagos, Nigeria
Adekoya BJ; Onakoya AO; Shah SP; Adepoju FG
Journal of Glaucoma 2014; 23: 41-45 (IGR: 14-3)

50286 Validity of Self-reported Eye Disease and Treatment in a Population-based Study: The Los Angeles Latino Eye Study
Patty L; Wu C; Torres M; Azen S; Varma R;
Ophthalmology 2012; 119: 1725-1730 (IGR: 14-2)

50515 Surveillance for ocular hypertension: an evidence synthesis and economic evaluation
Burr JM; Botello-Pinzon P; Takwoingi Y; Herná,ndez R; Vazquez-Montes M; Elders A; Asaoka R; Banister K; van der Schoot J; Fraser C; King A; Lemij H; Sanders R; Vernon S; Tuulonen A; Kotecha A; Glasziou P; Garway-Heath D; Crabb D; Vale L; Azuara-Blanco A; Perera R; Ryan M; Deeks J; Cook J.
Health Technol Assess 2012; 16: 1-271 (IGR: 14-2)

50320 An economic comparison of hospital-based and community-based glaucoma clinics
Sharma A; Jofre-Bonet M; Panca M; Lawrenson JG; Murdoch I
Eye 2012; 26: 967-971 (IGR: 14-2)

48981 The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma
Van Gestel A; Webers CA; Severens JL; Beckers HJ; Jansonius NM; Hendrikse F; Schouten JS
Acta Ophthalmologica 2012; 90: 20-31 (IGR: 14-1)

48930 The role of the expected value of individualized care in cost-effectiveness analyses and decision making
Van Gestel A; Grutters J; Schouten J; Webers C; Beckers H; Joore M; Severens J
Value in Health 2012; 15: 13-21 (IGR: 14-1)

48868 Shared care of patients with ocular hypertension in the Community and Hospital Allied Network Glaucoma Evaluation Scheme (CHANGES)
Mandalos A; Bourne R; French K; Newsom W; Chang L
Eye 2012; 26: 564-567 (IGR: 14-1)

47842 Identification of diseases for EQ-5d bolt-on item development: An empirical approach
Solem CT; Gu NY; Pickard AS
Value in Health 2011; 14: A428 (IGR: 13-4)

48296 Community optometrist referral of those aged 65 and over for raised IOP post-NICE: AOP guidance versus joint college guidance--an epidemiological model using BEAP
Vernon SA; Hillman JG; Macnab HK; Bacon P; van der Hoek J; Vernon OK; Bhargarva A
British Journal of Ophthalmology 2011; 95: 1534-1546 (IGR: 13-4)

48031 Gene patents related to common diseases of the eye
Sahebjada S; Cantsileris S; Baird PN
Recent Patents on DNA and Gene Sequences 2011; 5: 185-193 (IGR: 13-4)

47832 Economic outcomes of glaucoma treatment with prostaglandin eye drops preserved with polyquad(registered trademark) instead of benzalkonium chloride in Germany
Gerlier L; Lamotte M; Lorenz K; Berdeaux G; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A503 (IGR: 13-4)

47841 Cost-effectiveness of the ex-press glaucoma filtration device in France
de Jong L; Lafuma A; Clement O; Aguade AS; Berdeaux G
Value in Health 2011; 14: A250-A251 (IGR: 13-4)

47831 Cost of blindness in Austria
Brennig C; Schollbauer V; Walter E
Value in Health 2011; 14: A504-A505 (IGR: 13-4)

47820 Cost-offset analysis: Bimatoprost versus other prostaglandin analogues in open-angle glaucoma
Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
American Journal of Managed Care 2011; 17: e365-e374 (IGR: 13-4)

47546 Eye care utilization in Canada: Disparity in the publicly funded health care system
Jin Y-P; Trope GE
Canadian Journal of Ophthalmology 2011; 46: 133-138 (IGR: 13-4)

47611 Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review
Sarnes E; Crofford L; Watson M; Dennis G; Kan H; Bass D
Clinical Therapeutics 2011; 33: 1413-1432 (IGR: 13-4)

47839 Cost-effectiveness of the ex-press glaucoma filtration device in the Netherlands
de Jong L; Lafuma A; Aguade AS; Clement O; Berdeaux G
Value in Health 2011; 14: A250 (IGR: 13-4)

47836 Glaucoma management cost as a function of disease stage and treatment changes
Gerlier L; Shlaen R; Lorenz K; Lamotte M; Verboven Y; Pfeiffer N
Value in Health 2011; 14: A505 (IGR: 13-4)

48360 An assessment of the health and economic burdens of glaucoma
Varma R; Lee PP; Goldberg I; Kotak S
American Journal of Ophthalmology 2011; 152: 515-522 (IGR: 13-4)

47810 Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe
Hollo G; Thelen U; Teus MA; Quaranta L; Ferkova S; Babic N; Misiuk-Hojlo M; Mikropoulos DG; Kaluzny BJ; Kozobolis V
Journal of Ocular Pharmacology and Therapeutics 2011; 27: 493-498 (IGR: 13-4)

47902 Health economical aspects of telemedical glaucoma monitoring
Swierk T; Jurgens C; Grossjohann R; Flessa S; Tost F
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2011; 108: 342-350 (IGR: 13-4)

46989 Economic impact of primary open-angle glaucoma in Australia
Dirani M; Crowston JG; Taylor PS; Moore PT; Rogers S; Pezzullo ML; Keeffe JE; Taylor HR
Clinical and Experimental Ophthalmology 2011; (IGR: 13-3)

46874 A discrete event simulation to optimise the allocation of constrained hospital resources for glaucoma
Crane GJ; Karnon J; Kymes S; Casson R; Metcalfe A; Hiller JE
Value in Health 2011; 14: A55 (IGR: 13-3)

47090 Glaucoma costs in Denmark in treatment naive patients
Olsen J; Berdeaux G; Skov J
Acta Ophthalmologica 2011; (IGR: 13-3)

46878 Cost of glaucoma in the United Kingdom according to the UK GPRD
Salmon J; Lafuma A; Robert J; Berdeaux G
Value in Health 2010; 13: 398 (IGR: 13-3)

46876 Cost-effectiveness analysis of travoprost followed by fixed combination travoprost/timolol treatment sequence (T-TTFC) compared to latanoprost followed by latanoprost/timolol fixed combination (L-LTFC) for patients with open angle glaucoma or ocular hyper
Taylor M; Tan R
Value in Health 2010; 13: 509 (IGR: 13-3)

46471 National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical Excellence
Wonderling D; Sawyer L; Fenu E; Lovibond K; Laramee P
Annals of Internal Medicine 2011; 154: 758-765 (IGR: 13-3)

46871 Cost-effectiveness analysis of formulary management strategies for first-line agents used in open-angle glaucoma and ocular hypertension
Blaser DA; Ousterhout MM; Gagnon JM; Calabrese D
Value in Health 2011; 14: A55 (IGR: 13-3)

46875 Burden of disease in patients with glaucoma in China: Results from 2009 national health and wellness survey
Tang B; Annunziata K; Zhong Z; Dong P; Xuan J
Value in Health 2010; 13: 562-563 (IGR: 13-3)

46877 Costs and effects of fixed combination therapies in open angle glaucoma
Wickstrom J; Centofanti M; Johnson M
Value in Health 2010; 13: 399-400 (IGR: 13-3)

46879 Costs of glaucoma in Sweden - A pilot study
Svensson J; Berdeaux G; Bergstrom A; Forsby M; Ghatnekar O
Value in Health 2010; 13: 399 (IGR: 13-3)

46880 Development of a multiattribute instrument for estimating utilities (preference weights) in people with glaucoma from the national eye institute visual functioning questionnaire (NEI-VFQ)
Kymes S; Peters CM; Beusterien K; Kotak S; Grinspan J; Stwalley D; Pleil A
Value in Health 2011; 14: 56 (IGR: 13-3)

46882 Glaucoma disease progression states: Establishing a direct, quantitative link between visual field defects and utility loss
Gerlier L; Lamotte M; Verboven Y
Value in Health 2010; 13: 248 (IGR: 13-3)

46883 Predictive factors of glaucoma treatment cost in Germany
Lorenz K; Wolfram C; Claus V; Plesnila-Frank C; Verboven Y; Pfeiffer N
Value in Health 2010; 13: 398-399 (IGR: 13-3)

46881 Cost-effectiveness of brinzolamide/timolol fixed combination (BTFC) versus dorzolamide/timolol fixed combination (DTFC) for patients with open angle glaucoma in Korea and Taiwan
Tan R
Value in Health 2010; 13: 563 (IGR: 13-3)

46118 Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: An analysis based on the United Kingdom general practitioner research database
Lafuma A; Salmon JF; Robert J; Berdeaux G
Clinical Ophthalmology 2011; 5: 361-367 (IGR: 13-2)

45522 Trends in Glaucoma Medication Expenditure: Medical Expenditure Panel Survey 2001-2006
Lam BL; Zheng DD; Davila EP; Arheart KL; Ocasio MA; McCollister KE; Caban-Martinez AJ; Lee DJ
Archives of Ophthalmology 2011; (IGR: 13-2)

46198 Cost-effectiveness of glaucoma interventions in Barbados and Ghana
Wittenborn JS; Rein DB
Optometry and Vision Science 2011; 88: 155-163 (IGR: 13-2)

45976 Efficiency of glaucoma drug regulation in 5 European countries: A 1995-2006 longitudinal prescription analysis
De Natale R; Le Pen C; Berdeaux G
Journal of Glaucoma 2011; 20: 234-239 (IGR: 13-2)

28058 Economic considerations of the diagnosis and management for glaucoma in the developed world
Tuulonen A
Current Opinions in Ophthalmology 2011; 22: 102-109 (IGR: 13-1)

28140 Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs
Schmier JK; Lau EC; Covert DW
Clinical Ophthalmology 2010; 4: 1137-1143 (IGR: 13-1)

27704 Evaluation of compliance with the EGS Guidelines in Spain, using Achievable Benchmarks of Care (ABC®) methodology: The IMCA Study
Castejón-Cervero MA; Jiménez-Parras R; Fernandez-Arias I; Teus-Guezala MA; IMCA Study Group
European Journal of Ophthalmology 2011; 21: 149-155 (IGR: 13-1)

27124 A Canadian population-based study of vision problems: Assessing the significance of socioeconomic status
Perruccio AV; Badley EM; Trope GE
Canadian Journal of Ophthalmology 2010; 45: 477-483 (IGR: 12-4)

27551 Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma
Van Gestel A; Severens JL; Webers CA; Beckers HJ; Jansonius NM; Schouten JS
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2010; 13:4 358-367 (IGR: 12-4)

27224 A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients
Jothi R; Ismail AM; Senthamarai R; Pal S
Indian Journal of Pharmacology 2010; 42: 362-365 (IGR: 12-4)

27247 First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008
Schmier JK; Covert DW; Robin AL
Current Medical Research and Opinion 2010; 26: 2769-2777 (IGR: 12-4)

27406 Effect of physician remuneration fees on glaucoma procedure rates in Canada
Buys YM; Austin PC; Campbell RJ
Journal of Glaucoma 2010; (IGR: 12-4)

27185 Setting priorities for comparative effectiveness research: A case study using primary open-angle glaucoma
Li T; Ervin A-M; Scherer R; Jampel H; Dickersin K
Ophthalmology 2010; 117: 1937-1945 (IGR: 12-4)

26599 Value-based medicine for glaucoma
Hirneiss C; Kampik A; Neubauer AS
Ophthalmologe 2010; 107: 223-227 (IGR: 12-3)

26644 Glaucoma in India: Estimated burden of disease
George R; Ve RS; Vijaya L
Journal of Glaucoma 2010; 19: 391-397 (IGR: 12-3)

26722 Modeling complex treatment strategies: Construction and validation of a discrete event simulation model for glaucoma
Van Gestel A; Severens JL; Webers CAB; Beckers HJM; Jansonius NM; Schouten JSAG
Value in Health 2010; 13: 359-367 (IGR: 12-3)

26601 Health-economic aspects of glaucoma screening
Hirneiss C; Niedermaier A; Kernt M; Kampik A; Neubauer AS
Ophthalmologe 2010; 107: 143-149 (IGR: 12-3)

26608 The Peterborough scheme for community specialist optometrists in glaucoma: A feasibility study
Syam P; Rughani K; Vardy SJ; Rimmer T; Fitt A; Husain T; McInerney L; Broome D; Driver R; Wormald R
Eye 2010; 24: 1156-1164 (IGR: 12-3)

26413 The Increased Cost of Medical Services for People Diagnosed With Primary Open-Angle Glaucoma: A Decision Analytic Approach
Kymes SM; Plotzke MR; Li JZ; Nichol MB; Wu J; Fain J
American Journal of Ophthalmology 2010; 150: 74-81 (IGR: 12-3)

25841 Cost benefit analysis of bimatoprost compared with other prostaglandin analogues in patients with primary open angle glaucoma (POAG) in the United States: A payer's perspective
Berenson K; Arora S; Kymes S; Hollander DA; Fiscella R; Burk C; Patel V
Journal of Managed Care Pharmacy 2010; 16: 146 (IGR: 12-2)

26119 Treatment of Glaucoma in Clinical Practice: Four-year Results From a Patient Registry in France
Kobelt G; Texier-Richard B; Buchholz P; Bron A; Renard JP; Rouland JF; Nordmann JP
Journal of Glaucoma 2010; 19: 199-206 (IGR: 12-2)

26223 Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension
Kymes SM; Plotzke MR; Kass MA; Boland MV; Gordon MO
Archives of Ophthalmology 2010; 128: 613-618 (IGR: 12-2)

25823 Epidemiology of glaucoma and drug utilization in UK primary care
Maguire A; Thompson M
Pharmacoepidemiology and Drug Safety 2009; 18: S143 (IGR: 12-2)

25891 First-year treatment costs among new initiators of topical prostaglandin analogs: Pooled results
Schmier JK; Covert DW
Clinical Ophthalmology 2010; 4: 437-445 (IGR: 12-2)

26228 Hospital-based glaucoma clinics: what are the costs to patients?
Sharma A; Jofre-Bonet M; Panca M; Lawrenson JG; Murdoch I
Eye 2010; 24: 999-1005 (IGR: 12-2)

25018 Shared care in glaucoma: a national study of secondary care lead schemes in England
Vernon SA; Adair A
Eye 2010; 24: 265-269 (IGR: 12-1)

25460 First-year treatment costs among new initiators of topical prostaglandin analogs
Schmier J K; Covert D W; Robin A L
Clinical Ophthalmology 2009; 3: 637-644 (IGR: 12-1)

25455 Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
Bergstrom A; Maurel F; Le Pen C; Lamure E; Kent M; Bardoulat I; Berdeaux G
Clinical Ophthalmology 2009; 3: 471-481 (IGR: 12-1)

25014 The precautionary principle: what is the risk of reusing disposable drops in routine ophthalmology consultations and what are the costs of reducing this risk to zero?
Somner JE; Cavanagh DJ; Wong KK; Whitelaw M; Thomson T; Mansfield D
Eye 2010; 24: 361-363 (IGR: 12-1)

25419 Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs
Schwartz G F; Tan J; Kotak S
Journal of Ocular Pharmacology and Therapeutics 2009; 25: 555-561 (IGR: 12-1)

25361 Healthcare charges in patients with glaucoma who undergo laser trabeculoplasty
Pasquale L R; Walt J G; Stern L S; Wiederkehr D; Malangone E; Dolgitser M
Advances in Therapy 2009; 1-13 (IGR: 12-1)

25066 Association between the use of glaucoma medications and mortality
Stein JD; Newman-Casey PA; Niziol LM; Gillespie BW; Lichter PR; Musch DC
Archives of Ophthalmology 2010; 128: 235-240 (IGR: 12-1)

24821 Direct and indirect effects of visual impairment on mortality risk in older persons
Karpa MJ; Mitchell P; Beath K; Rochtchina E; Cumming RG; Wang JJ; Blue Mountains Eye Study
Archives of Ophthalmology 2009; 127: 1347-1353 (IGR: 11-4)

24655 A french economic model comparing cost-effectiveness of duotrav and xalacom in Glaucoma
Lafuma A; Laurendeau C; Berdeaux G
Value in Health 2009; 12: A455 (IGR: 11-4)

24650 Interventional procedures in glaucoma: resources and costs in five european countries
Lafuma A; Verboven Y; Darba J; Brueggenjuergen B; Gylee E; Berto P
Value in Health 2009; 12: A460 (IGR: 11-4)

24659 Cost effectiveness analysis of tafluprost compared with latanoprost on the treatment of primary open angle glaucoma in South Korea
Song HJ; Kang SH; Heo JH; Lee EK
Value in Health 2009; 12: A456-A457 (IGR: 11-4)

24649 The application of discrete event simulation to quantitative risk benefit analysis
Maguire A; Douglas I; Blak BT
Value in Health 2009; 12: A453 (IGR: 11-4)

24596 Healthcare charges in patients who transition from ocular hypertension to primary open-angle glaucoma based on ophthalmic coding data
Pasquale LR; Walt JG; Stern LS; Wiederkehr D; Malangone E; Dolgitser M
Advances in Therapy 2009; 1-12 (IGR: 11-4)

24657 Costs of glaucoma in Denmark
Olsen J; Berdeaux G
Value in Health 2009; 12: A455 (IGR: 11-4)

24865 The cost of care for people with impaired vision in Australia
Keeffe JE; Chou SL; Lamoureux EL
Archives of Ophthalmology 2009; 127: 1377-1381 (IGR: 11-4)

24656 An economic analysis to evaluate anti-glaucoma pharmacotherapy
Bhowmik D; Sansgiry SS
Value in Health 2009; 12: A75 (IGR: 11-4)

25005 Impact of the Activity-Based Financing (11(th) Version) on glaucoma surgery payment in hospital resources
Muselier A; Mathieu B; Aube H; Creuzot-Garcher C; Bron A
Journal Français d'Ophtalmologie 2009; 32: 701-706 (IGR: 11-4)

24651 How and why automated medical databases should be used to create background occurrences for drug outcomes and safety studies: Glaucoma in thin (UK)
Maguire A; Blak BT
Value in Health 2009; 12: A489 (IGR: 11-4)

24654 Micro-costing vs gross-costing in the estimation of costs for the pharmoeconomic evaluation of glaucoma in Korea
Kang SH; Lee EK
Value in Health 2009; 12: A234 (IGR: 11-4)

24227 The impact of a glaucoma nurse specialist role on glaucoma waiting lists
Slight C; Marsden J; Raynel S
Nursing praxis in New Zealand inc 2009; 25: 38-47 (IGR: 11-3)

24299 Creating patient value in glaucoma care: applying quality costing and care delivery value chain approaches--a five-year case study in the Rotterdam Eye Hospital
de Korne DF; Sol K; Custers T; van Sprundel E; van Ineveld BM; Lemij HG; Klazinga NS
International journal of health care quality assurance 2009; 22: 232-251 (IGR: 11-3)

24377 A critical review of the full economic evaluations of pharmacological treatments for glaucoma
Koleva D; De Compadri P; Virgili G; Nobili A; Garattini L
Journal of Medical Economics 2008; 11: 719-741 (IGR: 11-3)

24376 Modelling the lifetime economic consequences of glaucoma in France
Nordmann JP; Lafuma A; Berdeaux G
Journal of Medical Economics 2009; 12: 9-16 (IGR: 11-3)

24027 Trends in annual medicare expenditures for glaucoma surgical procedures from 1997 to 2006
Schmier JK; Covert DW; Lau EC; Robin AL
Archives of Ophthalmology 2009; 127: 900-905 (IGR: 11-3)

24256 First-year treatment patterns among new initiators of topical prostaglandin analogs
Schmier JK; Covert DW; Robin AL
Current Medical Research and Opinion 2009; 25: 851-858 (IGR: 11-3)

24447 Cost-effectiveness of latanoprost, travoprost and bimatoprost for the treatment of glaucoma in Norway, Sweden and Denmark, using a decision-analytic health economic model
Stewart WC; Stewart JA; Mychaskiw MA
International Journal of Ophthalmology 2009; 9: 812-816 (IGR: 11-3)

23859 The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology 2009; 116: 823-832 (IGR: 11-2)

23540 Cost of illness of glaucoma: A critical and systematic review
Fiscella RG; Lee J; Davis EJH; Walt J
PharmacoEconomics 2009; 27: 189-198 (IGR: 11-2)

24003 The relationship of mean deviation scores and resource utilization among patients with glaucoma: a retrospective United States and European chart review analysis
Berenson K; Kymes S; Walt JG; Siegartel LR
Journal of Glaucoma 2009; 18: 390-394 (IGR: 11-2)

22759 Population-Based Studies in Ophthalmology
Wong TY; Hyman L
American Journal of Ophthalmology 2008; 146: 656-663 (IGR: 11-1)

22502 Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model
Stewart WC; Stewart JA; Mychaskiw MA
Eye 2009; 23: 132-140 (IGR: 11-1)

22849 Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US
Cantor LB; Katz LJ; Cheng JW; Chen E; Tong KB; Peabody JW
Current Medical Research and Opinion 2008; 24: 2905-2918 (IGR: 11-1)

22919 The impact of co-payment increases on dispensings of government-subsidised medicines in Australia
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiology and Drug Safety 2008; 17: 1091-1099 (IGR: 11-1)

22944 Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: Analysis based on the UK general practitioner research database
De Natale R; Lafuma A; Berdeaux G
Clinical Drug Investigation 2009; 29: 111-120 (IGR: 11-1)

21468 Costs and persistence of carbonic anhydrase inhibitor versus α-2 agonists, associated with β-blockers, in glaucoma and ocular hypertension: An analysis of the UK-GPRD database
Lafuma A; Berdeaux G
Current Medical Research and Opinion 2008; 24: 1519-1527 (IGR: 10-3)

21472 Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries
Thygesen J; Aagren M; Arnavielle S; Bron A; Frohlich SJ; Baggesen K; Azuara-Blanco A; Buchholz P; Walt JG
Current Medical Research and Opinion 2008; 24: 1763-1770 (IGR: 10-3)

20983 Screening for open angle glaucoma: Systematic review of cost-effectiveness studies
Hernández R; Rabindranath K; Fraser C; Vale L; Blanco AA; Burr JM; OAG Screening Project Group
Journal of Glaucoma 2008; 17: 159-168 (IGR: 10-2)

21161 Disease progression and the need for neuroprotection in glaucoma management
Varma R; Peeples P; Walt JG; Bramley TJ
American Journal of Managed Care 2008; 14: S15-S19 (IGR: 10-2)

21097 Economic evaluation of screening for open-angle glaucoma
Hernandez RA; Burr JM; Vale LD
International Journal of Technology Assessment in Health Care 2008; 24: 203-211 (IGR: 10-2)

21159 Managed care and the impact of glaucoma
Reeder CE; Franklin M; Bramley TJ
American Journal of Managed Care 2008; 14: S5-S10 (IGR: 10-2)

21115 A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: A European perspective
Hommer A; Wickstrom J; Friis MM; Steeds C; Thygesen J; Ferreras A; Gouws P; Buchholz P
Current Medical Research and Opinion 2008; 24: 1057-1063 (IGR: 10-2)

20959 Health care charges for patients with ocular hypertension or primary open-angle glaucoma
Pasquale LR; Dolgitser M; Wentzloff JN; Stern LS; Doyle JJ; Chiang TH; Walt JG
Ophthalmology 2008; 115: 633-638 (IGR: 10-2)

21316 Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma
Bramley T; Peeples P; Walt JG; Juhasz M; Hansen JE
Archives of Ophthalmology 2008; 126: 849-856 (IGR: 10-2)

21134 An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases
Kymes SM
Ophthalmic Epidemiology 2008; 15: 76-83 (IGR: 10-2)

20531 Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: Analysis conducted on the United Kingdom General Practitioner Research Database
Lafuma A; Berdeaux G
Current Medical Research and Opinion 2007; 23: 3009-3016 (IGR: 10-1)

20692 Costs of vision impairment: Present and future issues
Keeffe JE
Expert Review of Pharmacoeconomics and Outcomes Research 2007; 7: 523-527 (IGR: 10-1)

20689 Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension.
Frenkel RE; Frenkel M; Toler A
BMC Ophthalmology 2007; 7: 16 (IGR: 10-1)

20310 Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis
Lachaine J; Hodge WG; Steffensen I; Murray C; Barnes D; Foerster V; Ducruet T; Mensinkai S
Canadian Journal of Ophthalmology 2008; 43: 33-41 (IGR: 10-1)

20643 Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France
Payet S; Denis P; Berdeaux G; Launois R
Clinical Drug Investigation 2008; 28: 183-198 (IGR: 10-1)

20392 Direct costs of blindness experienced by patients enrolled in managed care
Frick KD; Walt JG; Chiang TH; Doyle JJ; Stern LS; Katz LM; Dolgitser M; Hendlish SK
Ophthalmology 2008; 115: 11-17 (IGR: 10-1)

20322 The costs of treating glaucoma with combinations of topical drugs in Spain
Neymark N; Buchholz P; Honrubia F; Kobelt G
European Journal of Ophthalmology 2008; 18: 52-59 (IGR: 10-1)

20660 The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: A systematic review and economic evaluation
Burr JM; Mowatt G; Hernandez R; Siddiqui MAR; Cook J; Lourenco T; Ramsay C; Vale L; Fraser C; Azuara-Blanco A
Health Technol Assess 2007; 11: iii-170 (IGR: 10-1)

20530 Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: A United States perspective
Schmier JK; Covert DW; Robin AL
Current Medical Research and Opinion 2007; 23: 2867-2875 (IGR: 10-1)

20827 Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist
Peeters A; Schouten JS; Webers CA; Prins MH; Hendrikse F; Severens JL
Eye 2008; 22: 354-362 (IGR: 10-1)

20389 Cost-effectiveness of treating ocular hypertension
Stewart WC; Stewart JA; Nassar QJ; Mychaskiw MA
Ophthalmology 2008; 115: 94-98 (IGR: 10-1)

20341 Cost analysis of glaucoma medications
Rylander NR; Vold SD
American Journal of Ophthalmology 2008; 145: 106-113 (IGR: 10-1)

19789 Disease management programs for glaucoma: Has the vision become a reality?
Goldberg LD
Disease Management and Health Outcomes 2007; 15: 199-205 (IGR: 9-4)

19932 The socioeconomic impact among Egyptian glaucoma patients
Eldaly M; Hunter M; Khafagy M
British Journal of Ophthalmology 2007; 91: 1274-1275 (IGR: 9-4)

19812 Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension
Frenkel REP; Frenkel M; Toler A
BMC Ophthalmology 2007; 7: Article Number: 16 (IGR: 9-4)

20121 Daily cost of glaucoma medications in China
Gao Y; Wu L; Li A
Journal of Glaucoma 2007; 16: 594-597 (IGR: 9-4)

20082 Pharmacoeconomics of new medications for common chronic ophthalmic diseases
Hirsch JD; Morello C; Singh R; Robbins SL
Survey of Ophthalmology 2007; 52: 618-633 (IGR: 9-4)

19681 Practice of pharmaceutical care - Therapeutic drug monitoring and pharmacoeconomics of glaucoma
Ikeda H
Yakugaku Zasshi 2007; 127: 1441-1448 (IGR: 9-4)

19788 Refill rates and budget impact of glaucoma lipid therapy: A retrospective database analysis
Walt JG; Wilensky JT; Fiscella R; Chiang TH; Guckian A
Clinical Drug Investigation 2007; 27: 819-825 (IGR: 9-4)

19548 Depressive symptomatology, medication persistence, and associated healthcare costs in older adults with glaucoma
Jayawant SS; Bhosle MJ; Anderson RT; Balkrishnan R
Journal of Glaucoma 2007; 16: 513-520 (IGR: 9-3)

19592 Medical costs of glaucoma and ocular hypertension in Italian referral centres: a prospective study
Koleva D; Motterlini N; Schiavone M; Garattini L
Ophthalmologica 2007; 221: 340-347 (IGR: 9-3)

19566 Glaucoma in the United States and Europe: Predicting costs and surgical rates based upon stage of disease
Lee PP; Kelly SP; Mills RP; Traverso CE; Walt JG; Doyle JJ; Katz LM; Siegartel LR; Costs of Glaucoma Study Group
Journal of Glaucoma 2007; 16: 471-478 (IGR: 9-3)

19575 Cost of patients with primary open-angle glaucoma: A retrospective study of commercial insurance claims data
Lee PP; Levin LA; Walt JG; Chiang T; Katz LM; Dolgitser M; Doyle JJ; Stern LS
Ophthalmology 2007; 114: 1241-1247 (IGR: 9-3)

19506 Cost effectiveness and cost utility of an organized screening programme for glaucoma
Vaahtoranta-Lehtonen H; Tuulonen A; Aronen P; Sintonen H; Suoranta L; Kovanen N; Linna M; Läärä E; Malmivaara A
Acta Ophthalmologica Scandinavica 2007; 85: 508-518 (IGR: 9-3)

17972 Primary angle closure glaucoma: a developing world perspective
Thomas R; Sekhar GC; Parikh R
Clinical and Experimental Ophthalmology 2007; 35: 374-378 (IGR: 9-2)

18029 Rates of glaucoma medication utilization among older adults with suspected glaucoma, 1992 to 2002
Stein JD; Sloan FA; Lee PP
American Journal of Ophthalmology 2007; 143: 870-872 (IGR: 9-2)

17544 The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries
Mendis S; Fukino K; Cameron A; Laing R; Filipe Jr A; Khatib O; Leowski J; Ewen M
Bulletin of the World Health Organisation 2007; 85: 279-288 (IGR: 9-2)

17526 The economic implications of glaucoma: A literature review
Schmier JK; Halpern MT; Jones ML
PharmacoEconomics 2007; 25: 287-308 (IGR: 9-2)

18063 Costs of interventions for visual impairment
Taylor HR; Pezzullo ML; Nesbitt SJ; Keeffe JE
American Journal of Ophthalmology 2007; 143: 561-565 (IGR: 9-2)

18030 The impact of glaucoma coding in a large claims database
Lee PP; Levin LA; Walt JG; Chiang TH; Doyle JJ; Stern LS; Dolgitser M
American Journal of Ophthalmology 2007; 143: 867-870 (IGR: 9-2)

16810 The projected increase in glaucoma due to the aging population in Austria from 2001 to 2031: results based on data of the Salzburg-Moorfields Collaborative Glaucoma Study
Hitzl W; Bunce C; Reitsamer HA; Grabner G; Hornykewycz K
European Journal of Ophthalmology 2007; 17: 45-52 (IGR: 9-1)

16778 Cost-effective evaluation of the glaucoma suspect
Doshi A; Singh K
Current Opinions in Ophthalmology 2007; 18: 97-103 (IGR: 9-1)

16950 Association between vision loss and higher medical care costs in medicare beneficiaries. Costs are greater for those with progressive vision loss
Javitt JC; Zhou Z; Willke RJ
Ophthalmology 2007; 114: 238-245 (IGR: 9-1)

17188 Economic evaluation for ophthalmologists
Kuper H; Jofre-Bonet M; Gilbert C
Ophthalmic Epidemiology 2006; 13: 393-401 (IGR: 9-1)

16865 LXIII Edward Jackson Memorial Lecture: Eye care: dollars and sense
Taylor HR
American Journal of Ophthalmology 2007; 143: 1-8 (IGR: 9-1)

15159 Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study
Gieser DK; Tracy Williams R; O'Connell W; Pasquale LR; Rosenthal BP; Walt JG; Katz LM; Siegartel LR; Wang L; Rosenblatt LC
Journal of Glaucoma 2006; 15: 419-425 (IGR: 8-4)

15068 Screening for glaucoma in Canada: a systematic review of the literature
Einarson TR; Vicente C; Machado M; Covert D; Trope GE; Iskedjian M
Canadian Journal of Ophthalmology 2006; 41: 709-721 (IGR: 8-4)

14515 Aniridie: Study of the treatments and orientatives costs
Andres Lazaro AM; Bel Prieto E
Ciencia y Tecnologia Pharmaceutica 2006; 16: 47-60 (IGR: 8-4)

14633 Treating patients with primary open angle glaucoma or ocular hypertension with domestic and imported latanoprost drop: Comparison on efficacy and cost
Ma J-X
International Journal of Ophthalmology 2006; 6: 895-897 (IGR: 8-4)

15154 On the socio-economic relevance of glaucoma
Grub M; Rohrbach JM
Klinische Monatsblätter für Augenheilkunde 2006; 223: 793-795 (IGR: 8-4)

14850 Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: A systematic review of economic evidence
Orme M; Boler A
PharmacoEconomics 2006; 24: 743-750 (IGR: 8-4)

15250 Trends in cost of major eye diseases to medicare, 1991 to 2000
Salm M; Belsky D; Sloan FA
American Journal of Ophthalmology 2006; 142: 976-982 (IGR: 8-4)

14304 Compare of daily cost of ophthalmic solutions for glaucoma
Gao Y; Wu L-L; Li A-J
Ophthalmology in China 2006; 15: 127-129 (IGR: 8-3)

14224 The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries
Holmstrom S; Buchholz P; Walt J; Wickstrom J; Aagren M
Current Medical Research and Opinion 2006; 22: 897-905 (IGR: 8-3)

13995 Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan
Lee R; Hutnik CM
Canadian Journal of Ophthalmology 2006; 41: 449-456 (IGR: 8-3)

13979 Medicare prescription drug cards: effectiveness for patients with glaucoma
Mahadevia AA; Nundy S; Frick KD; Jampel HD
Archives of Ophthalmology 2006; 124: 1175-1179 (IGR: 8-3)

14255 Volume of one drop and daily cost of ophthalmic solution for glaucoma
Tomita T; Ikeda H; Tsukamoto H; Sugimoto A; Mishima HK; Kihira K
Japanese Journal of Clinical Ophthalmology 2006; 60: 817-820 (IGR: 8-3)

13582 Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension
Fiscella R; Walt J
Drugs and Aging 2006; 23: 39-47 (IGR: 8-2)

13720 Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications
Goldberg LD; Walt J
PharmacoEconomics 2006; 24: 251-264 (IGR: 8-2)

13940 Update on utilities and cost-utility analyses
Hollands H; Sharma S
Current Opinions in Ophthalmology 2006; 17: 223-227 (IGR: 8-2)

13938 Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden
Kobelt G; Jonsson B; Bergstrom A; Chen E; Linden C; Alm A
Acta Ophthalmologica Scandinavica 2006; 84: 363-371 (IGR: 8-2)

13939 Management of ocular hypertension: A cost-effectiveness approach from the Ocular Hypertension Treatment Study
Kymes SM; Kass MA; Anderson DR; Miller JP; Gordon MO; Ocular Hypertension Treatment Study Group (OHTS)
American Journal of Ophthalmology 2006; 141: 997-1008 (IGR: 8-2)

13651 Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK
Lafuma A; Brezin A; Lopatriello S; Hieke K; Hutchinson J; Mimaud V; Berdeaux G
PharmacoEconomics 2006; 24: 193-205 (IGR: 8-2)

13266 A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy
Christensen TL; Poulsen PB; Holmstrom S; Walt JG; Vetrugno M
Current Medical Research and Opinion 2005; 21: 1837-1843 (IGR: 8-1)

13267 The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients - a European perspective
Tuil E; Hommer AB; Poulsen PB; Christensen TL; Buchholz P; Walt J; Holmstrom S
International Journal of Clinical Pract 2005; 59: 1011-1016 (IGR: 8-1)

13351 Can the number of primary open angle glaucoma in Austria within 2001 to 2031 be estimated?
Hitzl W; Reitsamer HA; Grabner G; Hornykewcyz K
Spektrum der Augenheilkunde 2005; 19: 290-293 (IGR: 8-1)

13437 The rising cost of glaucoma drugs in Ireland 1996-2003
Knox FA; Barry M; McGowan B; O'Brien C
British Journal of Ophthalmology 2006; 90: 162-165 (IGR: 8-1)

13452 A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma
Lee PP; Walt JG; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman RM; Jampel HD
Archives of Ophthalmology 2006; 124: 12-19 (IGR: 8-1)

13429 A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden
Lindblom B; Nordmann JP; Sellem E; Chen E; Gold R; Polland W; Williamson W; Buchholz P; Walt JG; Groleau D
Acta Ophthalmologica Scandinavica 2006; 84: 74-83 (IGR: 8-1)

13411 Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications
Noecker RJ; Walt JG
American Journal of Ophthalmology 2006; 141: S15-S21 (IGR: 8-1)

13068 Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe
Traverso CE; Walt JG; Kelly SP; Hommer AH; Bron AM; Denis P; Nordmann JP; Renard JP; Bayer A; Grehn F
British Journal of Ophthalmology 2005; 89: 1245-1249 (IGR: 7-3)

12193 Health economical evaluation of the 'Salzburg-Moorfields-Collaborative-Glaucoma-Study': Present and future costs for a glaucoma screening program
Hitzl W; Hornykewycz K; Ortner C; Reitsamer H; Stollinger M; Grabner G
Spektrum der Augenheilkunde 2005; 19: 23-27 (IGR: 7-2)

12216 Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom
Le Pen C; Ligier M; Berdeaux G
Journal of Medical Economics 2005; 8: 67-84 (IGR: 7-2)

12270 The economic burden of glaucoma and ocular hypertension: Implications for patient management: A review
Rouland J-F; Berdeaux G; Lafuma A
Drugs and Aging 2005; 22: 315-321 (IGR: 7-2)

12298 Cost considerations of the new fixed combinations for glaucoma medical therapy
Ventura MP; Saheb NE; Solari HP; Saraiva VS; Vianna RN; Burnier MN Jr
Journal of Clinical Pharmacy and Therapeutics 2005; 30: 251-254 (IGR: 7-2)

12302 Association between corneal thickness, mean intraocular pressure, disease stability and severity, and cost of treatment in glaucoma: a Canadian analysis
Walker JH; Buys Y; Trope G; Vicente C; Einarson TR; Covert D; Iskedjian M
Current Medical Research and Opinion 2005; 21: 489-494 (IGR: 7-2)

11566 Association between mean intraocular pressure, disease stability and cost of treating glaucoma in Canada
Vicente C; Walker J; Buys Y; Einarson TR; Covert D; Iskedjian M
Current Medical Research and Opinion 2004; 20: 1245-1251 (IGR: 6-3)

11468 What is the direct cost of treatment of acute primary angle closure glaucoma? The Singapore model
Wang JC; Chew PT
Clinical and Experimental Ophthalmology 2004; 32: 578-583 (IGR: 6-3)

10611 Medical predictive factors of glaucoma treatment costs
Denis P; Lafuma A; Berdeaux G
Journal of Glaucoma 2004; 13: 283-90 (IGR: 6-2)

10840 Glaucoma therapy: Prescribing pattern and cost analysis
Sharma R; Khajuria R; Sharma P; Sadhotra P; Kapoor B; Kohli K; Sharma CL
JK Science 2004; 6: 88-92 (IGR: 6-2)

9882 Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers
Houde M; Castilloux AM; Tingey D; Assalian A; LeLorier J
Canadian Journal of Ophthalmology 2003; 38: 469-475 (IGR: 5-3)

9904 Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertension
Costagliola C; Parmeggiani F; Sebastiani A
Expert Opinion in Pharmacotherapy 2003; 4: 1775-1788 (IGR: 5-3)

10023 Cost of glaucoma in Canada: analyses based on visual field and physician's assessment
Iskedjian M; Walker J; Vicente C; Trope GE; Buys Y; Einarson TR; Covert D
Journal of Glaucoma 2003; 12: 456-462 (IGR: 5-3)

9073 Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France
Bernard LM; Althin R; Dhawan R; Grima DT; Lam A; Aballéa S
European Journal of Ophthalmology 2003; 13 (Suppl 4): S30-S43 (IGR: 5-2)

9072 Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study
Diestelhorst M; Schaefer CP; Beusterien KM; Plante KM; Fain JM; Mozaffari E; Dhawan R
European Journal of Ophthalmology 2003; 13 (Suppl 4): S21-S29 (IGR: 5-2)

9070 Medical therapy cost considerations for glaucoma
Fiscella RG; Green A; Patuszynski DH; Wilensky JT
American Journal of Ophthalmology 2003; 136: 18-25 (IGR: 5-2)

9074 Patient persistency with pharmacotherapy in the management of glaucoma
Reardon G; Schwartz GF; Mozaffari E
European Journal of Ophthalmology 2003; 13 (Suppl 4): S44-S52 (IGR: 5-2)

9071 Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year
Rouland JF; Le Pen C; Ophthalmologists of the Glaucoma Study
European Journal of Ophthalmology 2003; 13 (Suppl 4): S5-S20 (IGR: 5-2)

8073 A cost analysis of the prostaglandin analogs
Mick AB; Gonzalez S; Dunbar MT; McSoley J
Optometry 2002; 73: 614-619 (IGR: 4-3)

8078 An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension
Stewart WC; Leech J; Sharpe ED; Kulze J; Ellyn J; Day DG
American Journal of Management Care 2002; 8 S240-248 (IGR: 4-3)

8248 Health economics, economic evaluation, and glaucoma
Kobelt G
Journal of Glaucoma 2002; 11: 531-539 (IGR: 4-3)

8009 Incidence of iris colour change in latanoprost treated eyes
Teus MA; Arranz-Marquez E; Lucea-Suescun P
British Journal of Ophthalmology 2002; 86: 1085-1088 (IGR: 4-3)

3691 Trends in glaucoma surgery incidence and reimbursement for physician services in the Medicare population from 1995 to 1998
Paikal D; Yu F; Coleman AL
Ophthalmology 2002; 109: 1372-1376 (IGR: 4-2)

3692 Cost analysis of glaucoma medications: a three-year review
Vold SD; Riggs WL; Jackimiec J
Journal of Glaucoma 2002; 11: 354-358 (IGR: 4-2)

18389 Clinical spectrum of posterior ischemic optic neuropathy
Sadda SR; Nee M; Miller NR; Biousse V; Newman NJ; Kouzis A
American Journal of Ophthalmology 2001; 132: 743-750 (IGR: 3-3)

6418 An observational, retrospective two-year cost study in primary open-angle glaucoma and ocular hypertension in newly diagnosed patients
Rouland JF; Peigne G; Sellem E; Renard JP; Williamson W; Filippi JM; Cohn H; Hamard P; Abellan P; Chagnon A
Journal Français d'Ophtalmologie 2001; 24: 233-243 (IGR: 3-2)

6585 Costs of medical and surgical treatment of glaucoma
Calissendorff BM
Acta Ophthalmologica Scandinavica 2001; 79: 286-288 (IGR: 3-2)

6586 Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands
Oostenbrink JB; Rutten-van Mölken MPMH; Sluyter-Opdenoordt TS
Journal of Glaucoma 2001; 10: 184-191 (IGR: 3-2)

19233 Daily cost of ophthalmic solutions for treating glaucoma in Japan
Ikeda H; Sato E; Kitaura T; Fukuchi H; Kimura Y; Kihira K
Japanese Journal of Ophthalmology 2001; 45: 99-102 (IGR: 3-1)

6287 The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in the Netherlands: an observational study of costs and initial treatment success based on retrospective chart review
Oostenbrink JB; Rutten-van Moelken MP; Opdenoordt TS
Documenta Ophthalmologica 1999; 98: 285-299 (IGR: 2-2)

5920 Cost analysis of glaucoma medications
Vold SD; Wiggins DA; Jackimiec J
Journal of Glaucoma 2000; 9: 150-153 (IGR: 2-1)

15622 Cost considerations of medical therapy for glaucoma
Fiscella RG; Geller JL; Gryz LL; Wilensky J; Viana M
American Journal of Ophthalmology 1999; 128: 426-433 (IGR: 1-3)

12.4 Laser trabeculoplasty and other laser treatment of the angle (1117 abstracts found)

94782 Outcomes of selective laser trabeculoplasty in corticosteroid-induced ocular hypertension and glaucoma
AlObaida I
European Journal of Ophthalmology 2021; 0: 11206721211023310 (IGR: 22-2)

94799 Selective Laser Trabeculoplasty Versus MIGS: Forgotten Art or First-Step Procedure in Selected Patients with Open-Angle Glaucoma
Pahlitzsch M
Ophthalmology and therapy 2021; 10: 509-524 (IGR: 22-2)

94917 Comparison of Outcomes for Laser Trabeculoplasty after Kahook Dual Blade Goniotomy Versus in Goniotomy-Naive Eyes
Cho J
Ophthalmology and therapy 2021; 10: 905-912 (IGR: 22-2)

94762 MicroPulse Transscleral Laser Therapy - Fluence May Explain Variability in Clinical Outcomes: A Literature Review and Analysis
Grippo TM
Clinical Ophthalmology 2021; 15: 2411-2419 (IGR: 22-2)

94836 Comparison of Treatment Outcomes of Selective Laser Trabeculoplasty for Primary Open-Angle Glaucoma and Pseudophakic Primary Angle-Closure Glaucoma Receiving Maximal Medical Therapy
Chang PY
Journal of clinical medicine 2021; 10: (IGR: 22-2)

94704 Selective laser trabeculoplasty in steroid-induced and uveitic glaucoma
Zhou Y
Canadian Journal of Ophthalmology 2022; 57: 277-283 (IGR: 22-2)

94755 Educational intervention to adopt selective laser trabeculoplasty as first-line glaucoma treatment: Randomized controlled trial: Educational intervention on selective laser trabeculoplasty
Tran E
European Journal of Ophthalmology 2021; 0: 11206721211018365 (IGR: 22-2)

94294 Low-energy Selective Laser Trabeculoplasty Repeated Annually: Rationale for the COAST Trial
Realini T
Journal of Glaucoma 2021; 30: 545-551 (IGR: 22-2)

94699 Selective Laser Trabeculoplasty in the Treatment of Ocular Hypertension and Open-Angle Glaucoma: Clinical Review
Zgryźniak A
Journal of clinical medicine 2021; 10: (IGR: 22-2)

94971 The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial
Bengtsson B
Acta Ophthalmologica 2022; 100: e455-e462 (IGR: 22-2)

94939 Long-Term Outcomes of Selective Laser Trabeculoplasty for Open-Angle Glaucoma in the Caribbean
Realini T
American Journal of Ophthalmology 2021; 232: 83-89 (IGR: 22-2)

94768 Selective laser trabeculoplasty: A review
Landers J
Clinical and Experimental Ophthalmology 2021; 49: 1102-1110 (IGR: 22-2)

94917 Comparison of Outcomes for Laser Trabeculoplasty after Kahook Dual Blade Goniotomy Versus in Goniotomy-Naive Eyes
Hogan D
Ophthalmology and therapy 2021; 10: 905-912 (IGR: 22-2)

94836 Comparison of Treatment Outcomes of Selective Laser Trabeculoplasty for Primary Open-Angle Glaucoma and Pseudophakic Primary Angle-Closure Glaucoma Receiving Maximal Medical Therapy
Wang JY
Journal of clinical medicine 2021; 10: (IGR: 22-2)

94971 The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial
Lindén C
Acta Ophthalmologica 2022; 100: e455-e462 (IGR: 22-2)

94782 Outcomes of selective laser trabeculoplasty in corticosteroid-induced ocular hypertension and glaucoma
Al Owaifeer AM
European Journal of Ophthalmology 2021; 0: 11206721211023310 (IGR: 22-2)

94294 Low-energy Selective Laser Trabeculoplasty Repeated Annually: Rationale for the COAST Trial
Gazzard G
Journal of Glaucoma 2021; 30: 545-551 (IGR: 22-2)

94762 MicroPulse Transscleral Laser Therapy - Fluence May Explain Variability in Clinical Outcomes: A Literature Review and Analysis
Sanchez FG
Clinical Ophthalmology 2021; 15: 2411-2419 (IGR: 22-2)

94699 Selective Laser Trabeculoplasty in the Treatment of Ocular Hypertension and Open-Angle Glaucoma: Clinical Review
Przeździecka-Dołyk J
Journal of clinical medicine 2021; 10: (IGR: 22-2)

94755 Educational intervention to adopt selective laser trabeculoplasty as first-line glaucoma treatment: Randomized controlled trial: Educational intervention on selective laser trabeculoplasty
Sanvicente C
European Journal of Ophthalmology 2021; 0: 11206721211018365 (IGR: 22-2)

94762 MicroPulse Transscleral Laser Therapy - Fluence May Explain Variability in Clinical Outcomes: A Literature Review and Analysis
Sanchez FG
Clinical Ophthalmology 2021; 15: 2411-2419 (IGR: 22-2)

94799 Selective Laser Trabeculoplasty Versus MIGS: Forgotten Art or First-Step Procedure in Selected Patients with Open-Angle Glaucoma
Davids AM
Ophthalmology and therapy 2021; 10: 509-524 (IGR: 22-2)

94704 Selective laser trabeculoplasty in steroid-induced and uveitic glaucoma
Pruet CM
Canadian Journal of Ophthalmology 2022; 57: 277-283 (IGR: 22-2)

94939 Long-Term Outcomes of Selective Laser Trabeculoplasty for Open-Angle Glaucoma in the Caribbean
Shillingford-Ricketts H
American Journal of Ophthalmology 2021; 232: 83-89 (IGR: 22-2)

94699 Selective Laser Trabeculoplasty in the Treatment of Ocular Hypertension and Open-Angle Glaucoma: Clinical Review
Szaliński M
Journal of clinical medicine 2021; 10: (IGR: 22-2)

94917 Comparison of Outcomes for Laser Trabeculoplasty after Kahook Dual Blade Goniotomy Versus in Goniotomy-Naive Eyes
Salim M
Ophthalmology and therapy 2021; 10: 905-912 (IGR: 22-2)

94294 Low-energy Selective Laser Trabeculoplasty Repeated Annually: Rationale for the COAST Trial
Latina M
Journal of Glaucoma 2021; 30: 545-551 (IGR: 22-2)

94762 MicroPulse Transscleral Laser Therapy - Fluence May Explain Variability in Clinical Outcomes: A Literature Review and Analysis
Stauffer J
Clinical Ophthalmology 2021; 15: 2411-2419 (IGR: 22-2)

94939 Long-Term Outcomes of Selective Laser Trabeculoplasty for Open-Angle Glaucoma in the Caribbean
Burt D
American Journal of Ophthalmology 2021; 232: 83-89 (IGR: 22-2)

94755 Educational intervention to adopt selective laser trabeculoplasty as first-line glaucoma treatment: Randomized controlled trial: Educational intervention on selective laser trabeculoplasty
Hark LA
European Journal of Ophthalmology 2021; 0: 11206721211018365 (IGR: 22-2)

94799 Selective Laser Trabeculoplasty Versus MIGS: Forgotten Art or First-Step Procedure in Selected Patients with Open-Angle Glaucoma
Winterhalter S
Ophthalmology and therapy 2021; 10: 509-524 (IGR: 22-2)

94971 The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial
Heijl A
Acta Ophthalmologica 2022; 100: e455-e462 (IGR: 22-2)

94704 Selective laser trabeculoplasty in steroid-induced and uveitic glaucoma
Fang C
Canadian Journal of Ophthalmology 2022; 57: 277-283 (IGR: 22-2)

94836 Comparison of Treatment Outcomes of Selective Laser Trabeculoplasty for Primary Open-Angle Glaucoma and Pseudophakic Primary Angle-Closure Glaucoma Receiving Maximal Medical Therapy
Wang JK
Journal of clinical medicine 2021; 10: (IGR: 22-2)

94782 Outcomes of selective laser trabeculoplasty in corticosteroid-induced ocular hypertension and glaucoma
Alotaibi H
European Journal of Ophthalmology 2021; 0: 11206721211023310 (IGR: 22-2)

94762 MicroPulse Transscleral Laser Therapy - Fluence May Explain Variability in Clinical Outcomes: A Literature Review and Analysis
Marcellino G
Clinical Ophthalmology 2021; 15: 2411-2419 (IGR: 22-2)

94704 Selective laser trabeculoplasty in steroid-induced and uveitic glaucoma
Khanna CL
Canadian Journal of Ophthalmology 2022; 57: 277-283 (IGR: 22-2)

94699 Selective Laser Trabeculoplasty in the Treatment of Ocular Hypertension and Open-Angle Glaucoma: Clinical Review
Turno-Kręcicka A
Journal of clinical medicine 2021; 10: (IGR: 22-2)

94917 Comparison of Outcomes for Laser Trabeculoplasty after Kahook Dual Blade Goniotomy Versus in Goniotomy-Naive Eyes
Pratte EL
Ophthalmology and therapy 2021; 10: 905-912 (IGR: 22-2)

94971 The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial
Andersson-Geimer S
Acta Ophthalmologica 2022; 100: e455-e462 (IGR: 22-2)

94939 Long-Term Outcomes of Selective Laser Trabeculoplasty for Open-Angle Glaucoma in the Caribbean
Balasubramani GK
American Journal of Ophthalmology 2021; 232: 83-89 (IGR: 22-2)

94782 Outcomes of selective laser trabeculoplasty in corticosteroid-induced ocular hypertension and glaucoma
Alsafi A
European Journal of Ophthalmology 2021; 0: 11206721211023310 (IGR: 22-2)

94799 Selective Laser Trabeculoplasty Versus MIGS: Forgotten Art or First-Step Procedure in Selected Patients with Open-Angle Glaucoma
Zorn M
Ophthalmology and therapy 2021; 10: 509-524 (IGR: 22-2)

94971 The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial
Andersson-Geimer S
Acta Ophthalmologica 2022; 100: e455-e462 (IGR: 22-2)

94755 Educational intervention to adopt selective laser trabeculoplasty as first-line glaucoma treatment: Randomized controlled trial: Educational intervention on selective laser trabeculoplasty
Myers JS
European Journal of Ophthalmology 2021; 0: 11206721211018365 (IGR: 22-2)

94836 Comparison of Treatment Outcomes of Selective Laser Trabeculoplasty for Primary Open-Angle Glaucoma and Pseudophakic Primary Angle-Closure Glaucoma Receiving Maximal Medical Therapy
Huang TL
Journal of clinical medicine 2021; 10: (IGR: 22-2)

94294 Low-energy Selective Laser Trabeculoplasty Repeated Annually: Rationale for the COAST Trial
Kass M
Journal of Glaucoma 2021; 30: 545-551 (IGR: 22-2)

94971 The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial
Aspberg J
Acta Ophthalmologica 2022; 100: e455-e462 (IGR: 22-2)

94755 Educational intervention to adopt selective laser trabeculoplasty as first-line glaucoma treatment: Randomized controlled trial: Educational intervention on selective laser trabeculoplasty
Zhang Q
European Journal of Ophthalmology 2021; 0: 11206721211018365 (IGR: 22-2)

94971 The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial
Aspberg J
Acta Ophthalmologica 2022; 100: e455-e462 (IGR: 22-2)

94836 Comparison of Treatment Outcomes of Selective Laser Trabeculoplasty for Primary Open-Angle Glaucoma and Pseudophakic Primary Angle-Closure Glaucoma Receiving Maximal Medical Therapy
Hsu YR
Journal of clinical medicine 2021; 10: (IGR: 22-2)

94782 Outcomes of selective laser trabeculoplasty in corticosteroid-induced ocular hypertension and glaucoma
Ali Aljasim L
European Journal of Ophthalmology 2021; 0: 11206721211023310 (IGR: 22-2)

94971 The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial
Aspberg J
Acta Ophthalmologica 2022; 100: e455-e462 (IGR: 22-2)

94917 Comparison of Outcomes for Laser Trabeculoplasty after Kahook Dual Blade Goniotomy Versus in Goniotomy-Naive Eyes
King J
Ophthalmology and therapy 2021; 10: 905-912 (IGR: 22-2)